

CURRICULUM VITAE

NAME: René Sylvain Kahn

ADDRESS: Division of Neuroscience, Dept. of Psychiatry
University Medical Center Utrecht
Heidelberglaan 100
3584 CX Utrecht

TELEPHONE: +31-(0)88-7556025
+31-3(0)88-755443 (fax)

DATE OF BIRTH: 18 June 1954

PLACE OF BIRTH: Amsterdam, The Netherlands

TRAINING: 1972-79 School of Medicine, University Groningen, The Netherlands

1981-83 Psychiatry residencies, University Hospital Utrecht, The Netherlands

1983-85 Neurology residencies, Academisch Medisch Centrum, Amsterdam, The Netherlands

1985-1988 Fellowship Biological Psychiatry, Montefiore Hospital and Albert Einstein College of Medicine, New York, NY

1988-1992 Residencies Psychiatry, Mount Sinai Hospital/Bronx VA Medical Center, New York, NY

REGISTRATIONS 1986 Neuropsychiatrist, The Netherlands
1992 Medical License, State of Connecticut #032389
1993 Medical License, State of New York #191018

HONORS: 1985 Fulbright Scholarship
1989 Ramaer Medaille
2009 Member Royal Netherlands Academy for Arts and Sciences

FACULTY POSITIONS 1992-1993 Assistant Professor, Mount Sinai School of Medicine, New York, NY
1993-1994 Adjunct Associate Professor, Dept of Psychiatry, Mount Sinai School of Medicine, New York, NY
1993- Professor of Psychiatry, University Utrecht, The Netherlands

CLINICAL POSITIONS:

1980-81 Medical Officer, Dutch Army
1992-1993 Chief Research Unit Bronx Veterans Administration
Hospital Mount Sinai School of Medicine New York NY
1993- Head Department of Psychiatry University Medical
Center Utrecht
1996-1999 Chair Division of Psychiatry (psychiatry and Child
and adolescent psychiatry) University Medical Center Utrecht
1999-2002 Chair Research Division of Psychiatry (psychiatry and
Child and adolescent psychiatry) University Medical Center
Utrecht
2002- Chair Division of Neuroscience (combining de departments
of psychiatry, child and adolescent psychiatry, neurology,
neurosurgery, neurophysiology, pharmacology, rehabilitation
medicine) University Medical Center Utrecht

ADMINISTRATIVE AND SCIENTIFIC COMMITTEES:

1993- Chairman Department of Psychiatry, University Medical
Center, Utrecht
1994-1996 Scientific Program Committee Dutch Psychiatric
Association
1994 Treasurer Organizing Committee for the 9th Annual
Meeting of the European College for Neuropsychopharmacology
1994-1998 Scientific Review Board Dutch Science Organization,
division Hormonal Regulation and Neuroscience
1994-1998 Neuroscience Committee Dutch Science Organization
1994-1998 Executive Committee European College for
Neuropsychopharmacology (ECNP)
1995- Chair Regional Residency Training Program
1995-2001 Secretary Dutch Residency Training Supervisory
Board
1996-2000 IRB University Medical Center Utrecht
1997-2007 Chair National Psychiatry Boards
1997-1999 Medical Staff Committee UMC Utrecht
1998-1999 Vice Chair Scientific Review Board Dutch Science
Organization, division Hormonal Regulation and Neuroscience
1998-2000 National Residency Training Program Accreditation
Committee
1999-2001 Board of Directors, Dutch Science Organization
1999-2008 Workshopcommittee ECNP
1999-2002 High Level Expert Group of the European Committee
on the VIth Framework Program
2000-2002 Selectioncommittee PIONIER grant Dutch Science
Organization
2000-2003 Chair National Residency Training Program
Accreditation Committee
2000- Programcommittee Cognition, Dutch Science Organization
2000-2005 Chair Programcommittee Large Investments Dutch
Science Organization

2002-2005 Selectioncommittee Large Personal Grants Dutch
Science Organization
2002-2007 Treasurer Executive Committee ECNP
2003-2006 Chair Dutch Psychiatric Association
2006- Treasurer Schizophrenia International Research Society
2006- Neuroscience and Mental Health Board, Medical Research
Council, United Kindgom
2006- Scientific Advisory Group, CNS. European Medicine
Agency (EMA)
2007- Vice President ECNP
2007-2010 Selectioncommittee Large Personal Grants Dutch
Science Organization
2008- Netherlands Health Council
2008- Strategic Review Board, Neuroscience and Mental Health,
Medical Research Council, United Kingdom
2009- Royal Society of Arts and Sciences, the Netherlands
2010- NEURON (Network of European Funding for
Neuroscience Research)
2010- German Research Board (Deutsche
Forschungsgemeinschaft (DFG))

EDITORIAL BOARDS:

Schizophrenia Research
European Neuropsychopharmacology
Schizophrenia Bulletin
Early Intervention in Psychosis

AD-HOC REVIEWER:

American Journal of Psychiatry
Archives of General Psychiatry
Behavioral Brain Research
Biological Psychiatry
Brain
British Journal of Psychiatry
European Neuropsychopharmacology
European Psychiatry
International Clinical Psychopharmacology
Journal of Abnormal Psychology
Journal of Neurology
Journal of Neuroscience
Journal of Psychopharmacology
Lancet
Neuroimage
Neuropsychopharmacology
Psychopharmacology
Psychiatry Research
Schizophrenia Bulletin
Schizophrenia Research
Twin Research

PAST GRANTS:

PI. NIMH; "Serotonin function in treatment refractory schizophrenia" MH46957, \$110,800; 1990-1991

PI Janssen Research Foundation, "Risperidone in the treatment of the negative symptoms of schizophrenia", 64766/0207, \$ 71,595; 1992-1993

PI. Janssen Research Foundation, "Risperidone in the treatment of chronic schizophrenia", 64766/0208, \$ 82,025; 1992-1993

Co-PI. Stanley Foundation. The Dutch hunger winter and schizophrenia, \$ 140,000; 1994-1996

PI Solvay. Development of functional MRI, Dfl. 480,000; 1995-1999

Co-PI. Stanley Foundation. Incidence of psychotic illness in ethnic groups in the Hague, \$ 150,000; 1996-1998

Co-PI. NWO (Dutch Science Organization). A multicenter study on neurobiological and neuropsychological predictors of functional status in first-onset schizophrenia: social disabilities, burden on the family, needs for care and quality of life, Dfl. 613,000,-; 1996-2000

Co-PI. NWO (Dutch Science Organization). The neurodynamics of schizophrenia: correlates and functional consequences, Dfl. 1,070,000; 1999-2004

Co- PI. Stanley Foundation. Structural brain abnormalities in relation to genotype and environment, \$150,000; 1999-2001

PI Universitair Medisch Centrum Utrecht. Development of a high-throughput system for the genetic dissection of "complex" trait through association analysis, with the emphasis on specific psychiatric disorders, Dfl. 870,000; 1999-2002.

PI. NWO (Dutch Science Organization). Prevention of iatrogenic neurological impairment in schizophrenia: the Schizophrenia Termination of Pharmacotherapy (STOP)-trial, fl. 657,000; 2001-2003

Co-PI. Stanley Center Grant, \$ 300,000; 2001-2004

Co-investigator. NWO (Dutch Science Organization). Prediction and prevention of psychosis in youngsters entering regional institutions for ambulatory mental health care institutions, fl. 764,000; 2002-2005

Co-PI. NWO (Dutch Science Organization). Cognition. Quantitative genetic modelling of variation in cognitive brain maturation: A longitudinal study in pre-adolescent twins. € 668,772; 2001-2004

PI. Pfizer: Effect of olanzapine and ziprazidone on cognition in first-episode schizophrenia € 450,000; 2002-2005

PI. European Group for Research in Schizophrenia. European First Episode Schizophrenia Trial (Eufest) € 4,500,000; 2002-2006

PI. BMS: Aripiprazole in social cognition € 270,000; 2005-2007

CURRENT GRANTS:

PI. NWO (Dutch Science Organization). Vulnerability and resilience in first episode psychosis. € 4,300,000; 2003-2013

PI. AstraZeneca, Janssen-Cilag, Lilly, Additional support for Vulnerability and resilience in first episode psychosis. € 600,000; 2005-2010

Co-PI. TI Pharma – A translational pharmacogenomics approach to improve drug development strategies for psychiatric disorders. € 2,200,000; 2006-2010

Co-PI. MARIE CURIE Research Training Network, European Twin Study network on Schizophrenia (EUTwinsS) € 2,400,000; 2007-2011

Co-PI. NIMH (1R01MH078075) High-density Genome-wide Association Study in Schizophrenia \$3.800,000; 2006-2010

Co-PI. NWO (Dutch Science Organization) TOP grant 40-00812-98-08018 Determinants of the development of bipolar disorder: two follow-up studies € 600,000; 2009-20013

PI. EU 7th Framework Program. Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSe). € 11,200,000; 2010-2015

Co-PI. NIH/NIMH (1R01 MH090553) Genomic studies of bipolar disorder in a large cohort from The Netherlands. \$6,000,000; 2010-2015

PUBLICATIONS - RENÉ SYLVAIN KAHN

01. van Ree, J.M.; Innemee, H.; Louwerens, J.W., Kahn, R.S.; de Wied, D. Non-opiate beta-endorphin fragments and Dopamine: I. The neuroleptic-like gamma-endorphin fragments interfere with the behavioural effects elicited by small doses of apomorphine. Neuropharmacology, 1982; 21: 1095-1101
02. Verhoeven, W.M.A.; van Ree, J.M.; Westenberg, H.G.M.; Krul, J.M.; Brouwer, G.J.; Thijssen, J.H.H.; de Wied, D.; van Praag, H.M.; Ceulemans, D.L.S.; Kahn, R.S. Clinical, Biochemical and Hormonal aspects of treatment with Des-Tyr¹-Gamma- Endorphin in Schizophrenia. Psychiatry Research, 1984; 11: 329-346
03. Kahn, R.S.; Westenberg, H.G.M.; Jolles, J. Zimeldine Treatment of Obsessive-Compulsive Disorder. Biological and Neuropsychological aspects. Acta Psychiatrica Scandinavica, 1984; 69: 259-261
04. Kahn, R.S.; and Westenberg, H.G.M. 1-5-Hydroxytryptophan in the treatment of anxiety disorders. Journal of Affective Disorders, 1985; 8: 197-200
05. van Praag, H.M.; Lemus, C.Z.; Kahn, R.S. The pitfalls of serotonin precursors as challengers in hormonal probes of central serotonin activity. Psychopharmacology Bulletin, 1986; 22: 565-570
06. van Praag, H.M.; Lemus, C.Z.; Kahn, R.S. Hormonal probes of central serotonergic activity: do they really exist? Biological Psychiatry, 1987; 22: 86-98
07. Kahn, R.S.; Westenberg, H.G.M., Verhoeven, W.M.A.; Gispen-de Wied, C; Kamberbeek, W. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double blind comparison of 5-hydroxytryptophan, clomipramine and placebo. International Clinical Psychopharmacology, 1987; 2: 33-45
08. Den Boer, J.; Westenberg, H.G.M., Verhoeven, W.M.A., Kamerbeek, W.; Kahn, R.S. Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. International Clinical Psychopharmacology, 1987; 2: 21-32
09. van Praag, H.M.; Kahn, R.S.; Asnis, G.M.; Lemus, C.Z.; Brown, S. Therapeutic indications for serotonin-potentiating compounds. A hypothesis. Biological Psychiatry, 1987; 22: 205-212
10. van Praag, H.M.; Kahn, R.S.; Asnis, G.M.; Wetzler, S; Brown, S.L.; Bleich, A; Korn, M.L. Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders. Journal of Affective Disorders, 1987; 13: 1-8
11. Westenberg, H.G.M.; den Boer, J; Kahn R.S. Psychopharmacology of anxiety disorders: on the role of serotonin in the treatment of anxiety states and phobic disorders. Psychopharmacology Bulletin, 1987; 23: 145-149

12. Kahn, R.S.; van Praag, H.M.; Wetzler, S; Asnis G.M.; Barr, G. Serotonin and Anxiety Revisited. Biological Psychiatry, 1988; 23: 189-208
13. Bleich, A; Brown, S; Kahn, R.S.; van Praag, H.M. The role of serotonin in schizophrenia. Schizophrenia Bulletin, 1988; 14: 297-315
14. Kahn, R.S.; Wetzler, S; van Praag, H.M.; Asnis, G.M. Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Research, 1988; 25: 101-104
15. van Praag H.M.; Kahn R.S. L-5-Hydroxytryptophan in depression and anxiety. Praxis, 1988; 77: 40-46
16. Kahn, R.S.; Asnis, G.M.; Wetzler, S.; van Praag, H.M. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology, 1988; 96: 360-364
17. Kahn, R.S.; van Praag, H.M. A Serotonin hypothesis of panic disorder. Human Psychopharmacology, 1988; 3: 285-288
18. Wetzler, S.; Kahn, R.S.; Strauman, T; Dubro, A. Diagnosis of Major Depression by self-report. Journal of Personality Assessment, 1989; 53: 22-30
19. Kahn, R.S.; Cahn, W.; van Praag H.M. Pathogenese van Paniekstoornis. Nederlands Tijdschrift voor Geneeskunde, 1989; 133: 498-501
20. Kahn, R.S.; Wetzler, S; Asnis, G.M.; Kling, MA; Suckow, RF; van Praag, H.M. Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study. Psychopharmacology, 1990; 100: 339-344
21. Kahn, R.S.; van Praag, H.M. Panic Disorder: a pre-synaptic serotonin defect? Psychiatry Research, 1990; 31: 209-210 (letter)
22. Wetzler, S; Kahn, R.S.; Cahn, W; van Praag, H.M.; Asnis G.M. Psychological test characteristics of depressed and panic patients. Psychiatry Research, 1990; 31: 179-192
23. Kahn, R.S.; van Praag, H.M. Paniekstoornis: een beknopt overzicht. Tijdschrift voor Psychiatrie, 1990; 32: 390-405
24. Kahn, R.S.; Wetzler S.; Asnis, G.M.; Papolos, D.; van Praag, H.M. Serotonin receptor sensitivity in major depression. Biological Psychiatry, 1990; 28: 358-362
25. Kahn, R.S., Kalus, O.; Wetzler S.; Cahn, W.; Asnis, G.M.; van Praag, H.M. Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects. Psychiatry Research, 1990; 33: 189-198
26. Suckow, R.F.; Cooper, Th.B.; Kahn, R.S. High-performance liquid chromatographic method for the analysis of plasma m-chlorophenylpiperazine. Journal of Chromatography, 1990; 528: 228-234

27. van Praag, H.M.; Asnis, G.M.; Kahn, R.S.; Brown, S.L.; Korn, J.M.; Harkavy Friedman, J.M.; Wetzler, S. Nosological tunnel vision in biological psychiatry; a plea for a functional psychopathology, Annals of the New York Academy of Science 1990; 600: 501-510
28. van Praag, H.M.; Asnis, G.M., Kahn, R.S.; Brown, S.L.; Korn, M.; Friedman, J.M.; Wetzler, S. Monoamines and abnormal behavior: a multi-aminergic perspective, British Journal of Psychiatry, 1990; 157: 723-734
29. Kahn, R.S.; Amin, F.; Powchik, P.; Goldstein, M.; Apter, S.; Kerman, B.; Jaff, S.; Davidson, M. Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms, Progress in Neuropsychopharmacology and Biological Psychiatry, 1990; 14: 879-884
30. Kalus, O.; Kahn, R.S.; Wetzler, S.; Asnis, G.M.; van Praag, H.M. Hypersensitivity to m-chlorophenylpiperazine in a subject with subclinical panic attacks. Biological Psychiatry, 1990; 28: 1053-1057
31. Kahn, R.S. Book Review: Barlow, DH. Anxiety and its disorders. The nature and treatment of anxiety and panic, The Guilford Press, New York, 1988. Journal of Nervous and Mental Disorders, 1990; 178: 727
32. Davidson, M.; Kahn, R.S.; Warne, P.; Powchik, P.; Kaminski, R.; Apter, S.; Jaff, S.; Davis D.L. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation, Archives of General Psychiatry, 1991; 48: 73-76
33. Kahn, R.S.; Davidson, M.; Kanof, P.J.; McQueeney, R.F.; Singh, R.R.; Davis, K.L. Effects of indomethacin on plasma homovanillic acid concentration in normal subjects: a study of prostaglandin-dopamine interactions. Psychopharmacology, 1991; 103: 95-98
34. Kalus, O.; Asnis, G.M.; Rubinson, E.; Kahn, R.S.; Harkavy Friedman, J.M.; Iqbal, N.; Grosz, D.; van Praag, H.M.; Cahn, W. Desipramine treatment in panic disorder. Journal of Affective Disorders, 1991; 21: 239-244
35. Kahn, R.S.; Wetzler, S.; Asnis, G.M.; van Praag, H.M. Pituitary hormone responses to meta-chlorophenylpiperazine in panic disorder and healthy control subjects. Psychiatry Research, 1991; 37: 25-34
36. Wetzler, S.; Kahn, R.S.; Asnis, G.M.; Korn, M.; van Praag, H.M. Serotonin receptor sensitivity and aggression, Psychiatry Research, 1991; 37: 271-279
37. Davidson, M.; Kahn, R.S.; Knott, P.; Kaminsky, R.; Dumont, K.; Apter, S.; Davis, K.L. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations, Archives of General Psychiatry, 1991; 48: 910-913
38. Davis, K.L.; Kahn, R.S.; Ko, G.; Davidson, M. Dopamine in schizophrenia: a review and reconceptualization, American Journal of Psychiatry, 1991; 148: 1474-1486

39. Iqbal, N.; Asnis, G.M.; Wetzler, S.; Kahn, R.S.; Kay, S.; van Praag, H.M. The MCPP challenge test in schizophrenia: hormonal and behavioral responses, Biological Psychiatry, 1991; 30: 770-778
40. Kahn, R.S.; Wetzler, S. m-Chlorophenylpiperazine as a probe of serotonin function: a review, Biological Psychiatry, 1991; 30: 1139-1166
41. Harvey P.D.; Putnam, K.M.; Davidson, M; Kahn, R.S.; Powchik, P; McQueeney, R; Keefe, R.S.E.; Davis, K.L. Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. Psychiatry Research, 1991; 38: 285-292
42. Kahn, R.S.; van Praag, H.M. In antwoord op commentaar van Dr. van der Molen. Tijdschrift voor Psychiatrie, 1991; 33: 171-174 (letter)
43. Post, R.M.; Findling, R.L.; Kahn, R.S. Interfaces between seizures and affective disorders: the uses of visually mapping the evolution and longitudinal course of an illness. Mount Sinai Journal of Medicine, 1991; 58: 310-323
44. Siever, L.J.; Kahn, R.S.; Lawlor, B.; Trestman, R.L.; Lawrence, T.L.; Coccaro, E.F. II. Critical issues in defining the role of serotonin in the psychiatric disorders. Pharmacological Reviews, 1991; 43: 509-525
45. Kahn, R.S.; Davidson, M.; Hirschowitz, J.; Stern, R.G.; Moore, C.; Davis, K.L. Nocturnal growth hormone secretion in schizophrenic patients and healthy subjects, Psychiatry Research, 1992; 41: 155-161
46. Kalus, O.; Wetzler, S.; Kahn, R.S.; Asnis, G.M.; van Praag, H.M. A dose-response study of intravenous m-chlorophenylpiperazine in normal subjects, Psychopharmacology, 1992; 106: 388-390
47. Kahn, R.S.; van Praag, H.M. Panic Disorder: a biological perspective, European Neuropsychopharmacology, 1992; 2: 1-20
48. Kahn, R.S.; Siever, L.; Gabriel, S.; Amin, F.; Stern, R.G.; DuMont, K.; Apter, S.; Davidson M. Serotonin function in schizophrenia: effects of m-chlorophenylpiperazine in schizophrenic patients and healthy subjects. Psychiatry Research, 1992; 43: 1-12
49. Kahn, R.S.; Kling, M.; Wetzler, S.; Asnis, G.M.; van Praag, H.M. Effect of m-chlorophenylpiperazine on plasma arginine-vasopressin concentrations in healthy subjects. Psychopharmacology, 1992; 108: 225-228
50. Asnis, G.M.; Wetzler, S.; Sanderson, W.C.; Kahn, R.S.; van Praag, H.M. Functional interrelationship of serotonin and norepinephrine: cortisol response to MCPP and DMI in patients with panic disorder, patients with depression, and normal control subjects. Psychiatry Research, 1992; 43: 65-76
51. Davis, K.L.; Davidson, M; Kahn, R.S.; Ko, G. In reply to Dworkin & Opler, American Journal of Psychiatry, 1992; 149: 1285 (letter)

52. Galynker, I.; McQuiston, H.; Kahn, R.S.; Friedman, M. Fluoxetine treatment of slow eating, Journal of Clinical Psychiatry, 1992; 53: 295-296
53. Kahn, R.S.; Knott, P.; Gabriel, S.; DuMont, K.; Mastroianni, L.; Davidson, M. Effect of m-chlorophenylpiperazine on plasma homovanillic acid concentrations in healthy subjects. Biological Psychiatry, 1992; 32: 1055-1061
54. Davidson, M.; Kahn R.S.; Stern R.G.; Harvey P.D.; Keefe R.; Knott P.; Apter S.; Webster L.; Davis K.L. Measurements of plasma homovanillic acid in schizophrenic patients. Clinical Neuropharmacology, 1992; 15: 521A-522A
55. Davidson, M.; Kahn, R.S.; Davis, K.L. In reply to Volavka et al. Archives of General Psychiatry, 1992; 49: 999 (letter)
56. Kahn RS, Siever L, Davidson M, Greenwald C, Moore C. Haloperidol and clozapine treatment and their effect on M-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine. Psychopharmacology (Berl). 1993; 112(1 Suppl): S90-4.
57. Kahn, R.S.; Davidson, M. On the value of measuring dopamine, norepinephrine and their metabolites in schizophrenia. Neuropsychopharmacology, 1993; 8: 93-95 (editorial)
58. Davidson, M.; Kahn, R.S.; Stern R.G.; Hirschowitz, J.; Apter, S.; Knott, P.; Davis, K.L. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Research, 1993; 46:151-163
59. Kahn, R.S. Werking van clozapine bij schizofrenie: aanknopingspunten voor nieuwe farmacotherapeutica, Nederlands Tijdschrift voor Geneeskunde, 1993; 137:1440-1442
60. Stern RG, Kahn RS, Davidson M. Predictors of response to neuroleptic treatment in schizophrenia. Psychiatric Clinics of North America. 1993; 16: 313-38. Review.
61. Kahn, R.S.; Davidson, M.; Knott, P.; Stern, R.G.; Apter, S.A.; Davis, K.L. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment, Archives of General Psychiatry, 1993; 50: 599-605
62. Kahn, R.S.; Davidson, M.; Siever, L.; Gabriel, S.; Apter S.; Davis, K.L. Serotonin function and treatment response to clozapine in schizophrenic patients. American Journal of Psychiatry, 1993; 150: 1337-1342
63. Kahn, R.S.; Davidson, M.; Siever, L.; Greenwald, C.; Moore, C.; Davis, K.L. Haloperidol and clozapine treatment and their effect on m-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine. Psychopharmacology, 1993; 112: S90-S94
64. Kahn, R.S.; Davidson, M. Serotonin, dopamine and their interactions in schizophrenia: an editorial. Psychopharmacology, 1993; 112: S1-S4

65. Stern, R.G.; Kahn, R.S.; Harvey, P.D.; Amin, F.; Apter, S.; Hirschowitz, J. Early response to haloperidol treatment in chronic schizophrenia. Schizophrenia Research, 1993; 10: 165-171
66. Kahn, R.S.; Davidson, M. Serotonin receptor responsivity in schizophrenia. International Clinical Psychopharmacology, 1993; 8: 47-51
67. Kahn, R.S.; Harvey, P.D.; Davidson, M.; Keefe, R.S.E.; Neale, J.; Apter, S.; Mohs, R.C.; Davis, K.L. Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function. Schizophrenia Research, 1994; 11: 217-224
68. Kahn, R.S.; Trestman, R.; Weitzner, R.; Lawler, B.; Siever, L.; Davidson, M. Effects of ipsapirone in healthy subjects: a dose-response study. Psychopharmacology, 1994; 141: 155-160
69. Kahn, R.S.; Davidson, M.; Siever, L. Davis, K.L. Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazine. Biological Psychiatry, 1994; 35: 909-914
70. Baaré, W.F.C.; Hulshoff Pol, H.E.; Kahn, R.S. In-vivo morfologisch hersenonderzoek bij patiënten met schizofrenie. Tijdschrift voor Psychiatrie, 1994; 36: 726-735
71. Van Berckel, B.N.M.; Van Ree, J.M.; Kahn, R.S. Non-monoaminerge systemen bij schizofrenie. Tijdschrift voor Psychiatrie, 1994; 36: 762-775
72. Van Oel, C.J.; Hoek, H.W.; Kahn, R.S. Genetische epidemiologie van schizofrenie. Tijdschrift voor Psychiatrie, 1994; 36: 702-713
73. Kahn, R.S.; Westenberg, H.G.M. Dopamine en serotonine bij schizofrenie. Tijdschrift voor Psychiatrie, 1994; 36: 736-746
74. Stern, R.G.; Kahn, R.S.; Davidson, M.; Nora, R.M.; Davis, K.L. Early response to clozapine in schizophrenia. American Journal of Psychiatry, 1994; 151: 1817-1818
75. Kahn, R.S. De psychiater in zijn nieuwe rol. NRV Magazine, november 1994
76. Hulshoff Pol, H.E.; Baaré, W.; Mali, P.Th.M; Van Ree, J.M.; Kahn, R.S. Schizofrenie in beeld gebracht; afwijkingen in hersenanatomie en -metabolisme. Nederlands Tijdschrift voor Geneeskunde, 1995; 130: 494-497
77. Hoek, H.W.; Kahn R.S. Erfelijkheid en omgevingsfactoren in de etiologie van schizofrenie. Nederlands Tijdschrift voor Geneeskunde, 1995; 130: 498-501
78. Amin, F.; Davidson, M.; Kahn, R.S.; Schmeidler, J.; Stern, R.; Knott, P.J.; Apter, S. Assessment of the central dopaminergic index of plasma HVA in schizophrenia. Schizophrenia Bulletin, 1995; 21: 53-66
79. Kahn, R.S. Nieuwe ontwikkelingen in de farmacotherapie van psychiatrische aandoeningen. Bijblijven, 1995; 11: 6-11

80. Kahn R.S. Book Review: Fog, R.; Gerlach, J.; Hemmingsen, R. Schizophrenia, an integrated view, Munksgaard, Copenhagen. European Neuropsychopharmacology, 1995; 5: 55
81. Van Harten, P.N.; Matroos, G.E.; Hoek, H.W.; Kahn, R.S. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia. The Curaçao extrapyramidal syndromes study: I. Schizophrenia Research, 1996; 19: 195-203
82. Van Megen, H.J.G.M.; Westenberg, H.G.M.; Den Boer, J.A.; Kahn, R.S. The panic-inducing properties of the cholecystokinin tetrapeptide CCK₄ in patients with panic disorder. European Neuropsychopharmacology, 1996; 6: 187-194
83. Van Megen, H.J.G.M.; Westenberg, H.G.M.; Den Boer, J.A.; Kahn, R.S. Cholecystokinin in anxiety. European Neuropsychopharmacology, 1996; 6: 263-280
84. Handelsman, L.; Holloway, K.; Kahn, R.S.; Sturiano, C.; Rinaldi, P.J.; Bernstein, D.P.; Siever, L.; Gabriel, S.; Cooper, T.B. Hostility is associated with a low prolactin response to metachlorophenylpiperazine in abstinent alcoholics. Alcoholism: Clinical and Experimental Research, 1996; 20: 824-829
85. Van Berckel, B.N.M.; Kahn, R.S. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biological Psychiatry, 1996; 40: 1298-1300
86. Van Berckel, B.N.M.; Kahn, R.S. Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology, 1997; 16: 317-324
87. Van Veelen, N.M.J.; Kahn, R.S. Diabetes and depression: the biological interaction, Diabetes Research International, 1997; 6: 12-14
88. Selten J.-P., Slaets, J., Kahn R.S. Schizophrenia in Surinamese and Dutch Antillean immigrants to The Netherlands: evidence of an increased incidence. Psychological Medicine, 1997; 27: 807-811
89. Van Harten, P.N.; Matroos, G.E., Hoek, H.W., Kahn, R.S. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia. The Curaçao extrapyramidal syndromes study: II. Schizophrenia Research, 1997; 26: 235-242
90. Selten, J.-P., Slaets, J., Kahn R.S. Verhoogde indicentie van schizofrenie bij migranten uit Suriname en de Nederlandse Antillen. COBO-bulletin, 1997; 30: 41-44
91. Van Berckel, B.N.M.; Lipsch, C.; Timp, S.; Gispens-de Wied, C.; Wynne, H.; Van Ree, J.M.; Kahn, R.S. Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology, 1997; 16: 317-324
92. Selten, J.P.; Slaets, J.P.J.; Kahn, R.S. Prenatal exposure to influenza and schizophrenia in Surinamese and Dutch Antillean immigrants to The Netherlands. Schizophrenia Research, 1998; 30: 101-103
93. Van Meijel, B.; Van der Gaag, M.; Kahn, R.S. Vroegsignalering en vroege interventie bij patiënten met schizofrenie. Maandblad Geestelijke Volksgezondheid, 1998; 4: 347-360

94. Van Harten, P.N.; Hoek, H.W.; Matroos, G.E.; Koeter, M.; Kahn, R.S. Intermittent neuroleptic treatment and risk for tardive dyskinesia: The Curaçao extrapyramidal syndromes study: III. American Journal of Psychiatry, 1998; 155: 565-567
95. Jansma, J.M.; Ramsey, N.F.; Kahn, R.S. Tactile stimulation during finger opposition does not contribute to 2D fMRI brain activity pattern. Neuroreport, 1998; 9: 501-505
96. Amin, F.; Stroe, A.E.; Kahn, T.; Knott, P.J.; Kahn, R.S.; Davidson, M. Control of renal factors in plasma homovanillic acid measurements. Neuropsychopharmacology, 1998; 18: 317-320
97. Van Berckel, B.N.M.; Oranje, B.; Van Ree, J.M.; Verbaten, M.N.; Kahn, R.S. The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology, 1998; 137: 271-281
98. Kahn, R.S. Reactie op De (in)effectiviteit van psychofarmaca, Directieve Therapie, 1998; 18: 179-182
99. Van Berckel, B.N.M.; Lipsch, C.; Gispens-de Wied, C.; Wynne, H.J.; Blankenstein, M.A.; Van Ree, J.M.; Kahn, R.S. The partial NMDA agonist d-cycloserine stimulates LH secretion in healthy volunteers. Psychopharmacology, 1998; 138: 190-197
100. Jansen, L.M.C.; Gispens-de Wied, C.C.; Gademan, P.J.; De Jonge, R.C.J.; Van der Linden, J.A.; Kahn, R.S. Blunted cortisol response to a psychosocial stressor in schizophrenia. Schizophrenia Research, 1998; 33: 87-94
101. Handelsman, L.; Kahn, R.S.; Sturiano, Ch.; Rindaldi, P.J.; Gabriel, S.; Schmeidler, J.P.; Bernstein, D.P.; Siever, L.; Cooper, T.B. Hostility is associated with a heightened prolactin response to meta-chlorophenylpiperazine in abstinent cocaine addicts. Psychiatry Research, 1998; 80: 1-12
102. Hulshoff Pol, H.H. & Kahn, R.S. Beeldvormend onderzoek in de psychiatrie. Nederlands Tijdschrift voor Geneeskunde, 1998; 142: 2285-2290
103. Ramsey N.F.; Van den Brink, J.S.; Van Muiswinkel, A.M.C.; Folkers, P.J.M.; Moonen, C.T.W.; Jansma, J.M.; Kahn, R.S. Phase navigator correction in 3D fMRI improves detection of brain activation: quantitative assessment with a graded motor activation procedure. Neuroimage, 1998; 8: 240-248
104. Staal, W.G.; Hulshoff Pol, H.E., Schnack, H.; Van der Schot, A.C.; Kahn R.S. Partial volume decrease of the thalamus in relatives of patients with schizophrenia. American Journal of Psychiatry, 1998; 155: 784-1786
105. Van Meijel, B.; Van der Gaag, M.; Kahn, R.S.; Grypdonck, M. Effectieve toepassing van vroegsignalering en vroege interventie bij patiënten met schizofrenie. Verpleegkunde, 1999; 14: 22-33
106. Selten, J.-P.; Van der Graaf, Y.; Van Duursen, R.; Gispens-de Wied, C.C.; Kahn, R.S. Psychotic illness after prenatal exposure to the 1953 Dutch Flood Disaster. Schizophrenia Research, 1999; 35: 243-245

107. Oranje, B.; Van Berckel, B.N.M.; Kemner, C.; Van Ree, J.M.; Kahn, R.S. P50 Suppression and prepulse inhibition of the startle reflex in humans: a correlational study. Biological Psychiatry, 1999; 45: 883-890
108. Schouten, E.A.M.; d'Alfonso, A.A.L.; Nolen, W.A.; de Haan, E.H.F.; Wijkstra, J.; Kahn, R.S. Mood improvement from transcranial magnetic stimulation. American Journal of Psychiatry, 1999; 156: 669
109. Schouten, E.A.M.; d'Alfonso, A.A.L.; Nolen, W.A.; de Haan, E.H.F.; Wijkstra, J.; Kahn, R.S. Bepaalde effectiviteit van transcraniële magnetische stimulatie bij depressie. Een oriënterend onderzoek. Tijdschrift voor Psychiatrie, 1999; 4: 233-237
110. Staal, W.G.; Hulshoff Pol, H.E.; Kahn, R.S. Outcome of schizophrenia in relation to brain abnormalities. Schizophrenia Bulletin, 1999; 25: 337-348
111. van Veelen NM, Kahn RS. Dopamine, serotonin, and schizophrenia. Advances in Neurology. 1999; 80: 425-9. Review
112. Baaré, W.F.C.; Hulshoff Pol, H.H.; Hijman, R.; Mali, W.P.Th.; Viergever, M.A.; Kahn, R.S. Volumetric analysis of frontal lobe regions in schizophrenia: Relation to cognitive function and symptomatology. Biological Psychiatry, 1999; 45: 1597-1605
113. Aleman, A.; Hijman, R.; de Haan, E.H.F.; Kahn, R.S. Memory impairment in schizophrenia: a meta-analysis. American Journal of Psychiatry, 1999; 156: 1358-1366
114. Selten, J-P; Brown, A.S.; Moons, K.G.M.; Slaets, J.P.J.; Susser, E.S.; Kahn, R.S. Prenatal exposure to the 1957 influenza pandemic and non-affective psychosis in The Netherlands. Schizophrenia Research, 1999; 38: 85-91
115. Kahn, R.S. Book Review: Rooijmans, H.G.M. Negenennegentig jaar tussen wal en schip, geschiedenis van de Leidse Universitaire Psychiatrie (1899-1998), Bohn Stafleu Van Loghum, Houten. Nederlands Tijdschrift voor Geneeskunde, 1999; 143: 644
116. Van Berckel, B.N.M.; Evenblij, C.N.; Van Loon, B.J.A.M.; Maas, M.F.; Van der Geld, M.A.M.; Wynne, H.J.; Van Ree, J.M.; Kahn, R.S. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology, 1999; 21: 203-210
117. Van Harten, P.N.; Hoek, H.W.; Kahn, R.S. Acute Dystonia induced by drug treatment. British Medical Journal, 1999; 319: 623-626
118. Sommer, I.E.; Ramsey, N.F.; Bouma, A.; Kahn, R.S. Cerebral mirror-imaging in a monozygotic twin. The Lancet, 1999; 354: 1445-1446
119. Van Harten, P.N.; Kahn, R.S. Tardive Dystonia. Schizophrenia Bulletin, 1999; 25: 741-748
120. Oranje, B.; Van Berckel, B.N.M.; Kemner, C.; Van Ree, J.M.; Kahn, R.S.; Verbaten, M.N. The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology, 2000; 22: 293-302

121. Jansen, L.M.C.; Gispen-de Wied, C.C.; Kahn, R.S. Selective impairments in the stress response in schizophrenic patients. Psychopharmacology, 2000; 149: 319-325
122. Selten, J-P.; Van der Graaf, Y.; Dijkgraaf, M.; Edlinger, M.; Kahn, R.S. Seasonality of schizophrenia and stillbirths in The Netherlands. Schizophrenia Research, 2000; 44: 105-111
123. Kahn, R.S. Atypische antipsychotica. Nederlands Tijdschrift voor Geneeskunde, 2000; 144: 1627-1630
124. Staal, W.G.; Hijman, R.; Hulshoff Pol, H.E.; Kahn, R.S. Neuropsychological dysfunctions in siblings discordant for schizophrenia. Psychiatry Research, 2000; 95: 227-235
125. Staal, W.G.; Hulshoff Pol, H.E.; Schnack, H.G.; Hoogendoorn, M.L.C.; Jellema, K.; Kahn, R.S. Structural brain abnormalities in patients with schizophrenia and their healthy siblings. American Journal of Psychiatry, 2000; 157: 416-421
126. Selten, J-P.; Van der Graaf, Y.; Dijkgraaf, M.; Edlinger, M.; Kahn, R.S. Is schizofrenie seizoensgebonden? Nederlands Tijdschrift voor Geneeskunde, 2000; 144: 2278
127. Hulshoff Pol, H.E.; Hoek, H.W.; Susser, E.; Brown, A.S.; Dingemans, A.; Schnack, H.G.; Van Haren, N.E.M.; Ramos, L.M.P.; Gispen-de Wied, C.C.; Kahn, R.S. Prenatal exposure to famine and brain morphology in schizophrenia. American Journal of Psychiatry, 2000; 157: 1170-1172
128. Jansma, J.M.; Ramsey, N.F.; Coppola, R.; Kahn, R.S. Specific versus non-specific brain activity in a parametric N-back task. NeuroImage, 2000; 12: 688-697
129. Hulshoff Pol, H.E.; van der Flier, W.M.; Schnack, H.G.; Tulleken, C.A.F.; Ramos, L.M.; van Ree, J.M.; Kahn, R.S. Frontal lobe damage and thalamic volume changes. Neuroreport, 2000; 11: 3039-3041
130. Wijkstra, J.; Nolen, W.W.; Algra, A.; van Vliet, I.M.; Kahn, R.S. Relapse prevention in major depressive disorder after successful ECT: a literature review and a naturalistic case series. Acta Psychiatrica Scandinavica, 2000; 102: 454-460
131. Böcker, K.B.E.; Hijman, R.; Kahn, R.S.; De Haan, E.H.F. Perception, mental imagery and reality discrimination in hallucinating and non-hallucinating schizophrenia patients. British Journal of Clinical Psychology, 2000; 39: 397-406
132. Sitskoorn, M.M.; Appels, M.C.; Hulshoff Pol, H.E.; Kahn, R.S. Evidence of fronto-thalamic involvement in schizophrenia. Progress in Brain Research, 2000; 126: 343-355
133. Posthuma, D.; de Geus, E.J.; Neale, M.C.; Hulshoff Pol, H.E.; Baaré, W.F.C.; Kahn, R.S.; Boomsa, D.I. Multivariate genetic analysis of brain structure in an extended twin design. Behavior Genetics, 2000, 30: 311-319
134. Schnack, H.G.; Hulshoff Pol, H.E.; Baaré, W.F.C.; Staal, W.G.; Viergever, M.A.; Kahn, R.S. Automated separation of gray and white matter from MR images of the human brain. Neuroimage, 2001; 13: 230-237

135. Baaré, W.F.C.; Van Oel, J.; Hulshoff Pol, H.E.; Schnack, H.G.; Durston, S.; Sitskoorn, M.M.; Kahn, R.S. Volumes of brain structures in twins discordant for schizophrenia. Archives of General Psychiatry, 2001; 58: 33-40
136. Ramsey, N.F.; Sommer, I.E.C.; Rutten, G.J.; Kahn, R.S. Combined analysis of language tasks in fMRI improves assessment of hemispheric dominance for language functions in individual subjects. NeuroImage, 2001; 13: 719-733
137. Scheepers, F.E.; Gispen-de Wied, C.C.; Hulshoff Pol, H.E.; Van de Flier, W.; Van der Linden, J.A.; Kahn, R.S. The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. Neuropsychopharmacology, 2001; 24: 47-54
138. Sommer, I.; Aleman, A.; Ramsey, N.; Bouma, A.; Kahn, R.S. Handedness, language lateralisation and anatomical asymmetry in schizophrenia; a meta-analysis. British Journal of Psychiatry, 2001; 178: 344-351
139. Selten, J.-P.; Veen, N.; Feller, W.; Blom, J.D.; Schols, D.; Camoenië, W.; Oolders, J.; Van der Velden, M.; Hoek, H.W.; Vladar Rivero, V.M.; Van der Graaf, Y.; Kahn, R.S. Incidence of psychotic disorders in immigrant groups to The Netherlands. British Journal of Psychiatry, 2001, 178: 367-372
140. Scheepers F.E.; Gispen-de Wied, C.C.; Hulshoff Pol, H.E.; Kahn, R.S. Effect of clozapine on caudate nucleus volume in relation to symptoms of schizophrenia. American Journal of Psychiatry, 2001; 158: 644-666
141. Lampe I.K.; Kahn, R.S.; Heeren, T.J. Apathy, anhedonia, and psychomotor retardation in elderly psychiatric patients and healthy elderly individuals. Journal Geriatric Psychiatry Neurology, 2001; 14: 11-16
142. Schnack, H.G.; Hulshoff Pol, H.E.; Baaré, W.F.C.; Viergever, M.A.; Kahn, R.S. Automatic segmentation of the ventricular system from MR images of the human brain. NeuroImage, 2001, 14: 95-104
143. Staal, W.G.; Hulshoff Pol, H.E.; Schnack, H.G.; van Haren, N.; Seifert, N.; Kahn, R.S. Structural brain abnormalities in chronic schizophrenia at the extremes of the outcome spectrum. American Journal of Psychiatry, 2001; 158: 1140-1142
144. Scheepers FE, Gispen-de Wied CC, Westenberg HG, Kahn RS. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology. 2001; 25: 468-75.
145. Aleman, A.; Kahn, R.S. Effect of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. European Neuropsychopharmacology, 2001; 11: 289-293
146. Baaré, W.F.C.; Hulshoff Pol, H.E.; Boomsma, D.I.; Posthuma, D.; de Geus, E.F.C.; Schnack, H.G.; van Haren, N.E.M.; van Oel, C.L.; Kahn, R.S. Quantitative genetic modeling of variation in human brain morphology. Cerebral Cortex, 2001; 11: 816-824

147. Kossen M, Selten JP, Kahn RS. Elevated clozapine plasma level with lamotrigine. American Journal of Psychiatry. 2001; 158 :1930
148. Jansma, J.M.; Ramsey, N.F.; Slagter, H.A.; Kahn, R.S. Functional correlates of controlled and automatic processing. Journal of Cognitive Neuroscience, 2001; 13: 730-743
149. Van Oel C.J.; Baaré, W.F.C.; Hulshoff Pol, H.E.; Haag, J.; Balazs, J.; Dingemans, A.; Kahn, R.S.; Sitskoorn, M.M. Differentiating between low and high susceptibility to schizophrenia in twins: the significance of dermatoglyphic indices in relation to other determinants of brain development. Schizophrenia Research, 2001; 52: 181-193
150. Hulshoff Pol, H.E.; Schnack, H.G.; Mandl, R.C.W.; van Haren, N.E.M.; Koning, H.; Collins, D.L.; Evans, A.C.; Kahn, R.S. Focal gray matter density changes in schizophrenia. Archives of General Psychiatry, 2001; 58: 1118-1125
151. Scheepers, F.E.; Gispen-de Wied, C.C.; Kahn, R.S. The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia. Journal of Clinical Psychopharmacology, 2001; 21: 575-582
152. Sommer, I.E.; Ramsey, N.F.; Kahn, R.S. Language lateralisation in schizophrenia, an fMRI study. Schizophrenia Research, 2001; 52: 57-67
153. Hulshoff Pol, H.E.; Posthuma, D.; Baaré, W.F.C.; De Geus, E.J.C.; Schnack, H.G.; Van Haren, N.E.M.; Van Oel, C.J.; Kahn, R.S.; Boomsma D.I. Twin-singleton differences in brain structure using structural equation modelling. Brain, 2002; 125: 1-7
154. Selten, J.-P.; Bosman, I.J.; de Boer, D.; Veen, N.D.; van der Graaf, Y; Maes, R.A.A.; Kahn, R.S. Hair analysis for cannabinoids and amphetamines in a psychosis incidence study. European Neuropsychopharmacology, 2002; 12: 27-30
155. Hulshoff Pol, H.E.; Schnack, H.G.; Bertens, M.G.B.C.; Van Haren, N.E.M.; van der Tweel, I.; Staal, W.G.; Baaré, W.F.C.; Kahn, R.S. Volume changes in gray matter in patients with schizophrenia. American Journal of Psychiatry, 2002; 159: 244-250
156. Sommer, I.E.; Aleman, A.; Selten, J.-P.; Ramsey, N.F.; Bouma, A.; Kahn, R.S. Lateralisatie bij schizofrenie: een meta-analyse. Tijdschrift voor Psychiatrie, 2002; 44: 107-118
157. d'Alfonso, A.A.; Aleman, A.; Kessels, R.P.C; Schouten, E.A.; Postma, A.; Van der Linden, J.A.; Cahn, W.; Greene, Y.; de Haan, E.H.F; Kahn, R.S. Transcranial magnetic stimulation of left auditory cortex in patients with schizophrenia: effects on hallucinations and neurocognition. Journal of Neuropsychiatry and Clinical Neuroscience, 2002; 14: 77-79
158. Vollema, M.G.; Sitskoorn, M.M.; Appels, M.C.M; Kahn, R.S. Does the schizotypal personality questionnaire reflect the biological-genetic vulnerability to schizophrenia? Schizophrenia Research, 2002; 54: 39-45
159. Hanoeman, M.; Selten, J.-P.; Kahn, R.S. Incidence of schizophrenia in Surinam. Schizophrenia Research, 2002; 54: 219-221

160. Posthuma, D.; Baaré, W.F.C.; Hulshoff Pol, H.E.; Kahn, R.S.; Boomsma, D.I. The association between brain volume and intelligence is of genetic origin. Nature Neuroscience, 2002; 5: 83-84
161. Aleman, A.; de Haan, E.H.; Kahn, R.S.. Insight and neurocognitive function in schizophrenia. Journal of Neuropsychiatry and Clinical Neuroscience, 2002; 14: 241-242
162. Aleman A.; Schutter, D.J.; Ramsey, N.F.; van Honk, J.; Kessels, R.P.; Hoogduin, J.M.; Postma, A.; Kahn, R.S.; de Haan, E.H. Functional anatomy of top-down visuospatial processing in the human brain: evidence from rTMS. Cognitive Brain Research, 2002; 14: 300-302
163. Appels, M.C.; Sitskoorn, M.M.; de Boo, M.; Klumpers, U.; Kemps, A.; Elderson, A.; Kahn, R.S. Neurological signs in parents of schizophrenic patients. Neuroreport, 2002; 13: 575-579
164. Raemaekers, M.; Jansma, J.M.; Cahn, W.; Van der Geest, J.N.; Van der Linden, J.A.; Kahn, R.S.; Ramsey, N.F. Neuronal substrate of the saccadic inhibition deficit in schizophrenia investigated with 3-dimensional event-related functional magnetic resonance imaging. Archives of General Psychiatry, 2002; 59: 313-320
165. Scheepers, F.E.; Gispen-de Wied, C.C.; Westenberg, H.G.M.; Kahn, R.S. Effect of olanzapine on glutamate levels in cerebrospinal fluid of patients with schizophrenia. Journal of Clinical Psychopharmacology, 2002; 22: 333-334
166. Selten, J.P.; Cantor-Graae, E.; Slaets, J.; Kahn, R.S.. Odegaard's selection hypothesis revisited: schizophrenia in Surinamese immigrants to The Netherlands. American Journal of Psychiatry, 2002; 159: 669-671
167. Sitskoorn, M.M.; Nuyen, J.; Appels, M.C.; van der Wee, N.J.; Kahn, R.S. Release from proactive inhibition in schizophrenia and its potential as a genotypic marker. Journal of Clinical and Experimental Neuropsychology, 2002; 24: 67-81
168. Van Meijel, Van Der Gaag, M.; Kahn, R.S.; Grypdonck, M. The practice of early recognition and early intervention to prevent psychotic relapse in patients with schizophrenia: an exploratory study. Part 1. Journal of Psychiatric and Mental Health Nursing 2002; 9: 347-355
169. Van Meijel, B.; Van Der Gaag, M.; Kahn, R.S.; Grypdonck, M. The practice of early recognition and early intervention to prevent psychotic relapse in patients with schizophrenia: an exploratory study. Part 2. Journal of Psychiatric and Mental Health Nursing., 2002; 9: 357-363
170. Selten JP, Kahn RS. Schizophrenia after prenatal exposure to *Toxoplasma gondii*? Clinical Infectious Disorders. 2002; 35: 633-4
171. Kahn, R.S. Letter to the Editors. New study designs for new antipsychotics. Psychopharmacology, 2002; 162: 92
172. Veen, N.; Selten, J.P.; Hoek, H.W.; Feller, W.; Graaf, Y. van der; Kahn, RS. Use of illicit substances in a psychosis incidence cohort: a comparison among different ethnic groups in the Netherlands. Acta Psychiatrica Scandinavica, 2002; 105: 440-443

173. Ramsey, N.F.; Koning, H.A.M.; Welles, P.; Cahn, W.; Linden, J.A. van der; Kahn, R.S. Excessive recruitment of neural systems subserving logical reasoning in schizophrenia. Brain, 2002; 125: 1793-1807
174. Oranje, B.; Van Oel, C.L.; Gispens-de Wied, C.C.; Verbaten, N.M.; R.S. Kahn. Effects of Typical and Atypical Antipsychotics on the Prepulse Inhibition of the Startle Reflex in Patients with Schizophrenia. Journal of Clinical Psychopharmacology, 2002; 4: 359-365
175. Aleman, A.; Haan, E.H.F. de; Bócker, K.B.E.; Hijman, R.; Kahn, R.S. Letter to the Editors, Hallucinations in schizophrenia: imbalance between imagery and perception? Schizophrenia Research, 2002; 57: 315-316
176. Cahn, W.; Hulshoff Pol, H.E.; Bongers, M.; Schnack, H.G.; Mandl, R.C.W.; van Haren, N.E.M.; Durston, S.; Koning, H.; van der Linden, J.A.; Kahn, R.S. Brain morphology in antipsychotic-naïve schizophrenia: a study of multiple brain structures. British Journal of Psychiatry, 2002; 181 (suppl.43): s66-s72
177. Vorstman JA, de Ranitz AG, Udink ten Cate FE, Beemer FA, Kahn RS. A bifid uvula in a patient with schizophrenia as a sign of 22q11 deletion syndrome. Nederlands Tijdschrift voor Geneeskunde. 2002; 146: 2033-6. Dutch.
178. Aleman, A and Kahn RS. Open Peer Commentary. Top-down modulation, emotion, and hallucination. Behavioral and Brain Science, 2002; 25: 578
179. Oranje B, Gispens-de Wied CC, Verbaten MN, Kahn RS. Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidol. Biological Psychiatry. 2002; 52: 887-95
180. Cahn, W.; Hulshoff Pol, H.E.; Lems, E.B.T.E.; van Haren, N.E.M.; Schnack, H.G.; van der Linden, J.A.; Schothorst, P.F.; van Engeland, H.; Kahn, R.S. Brain volume changes in first-episode schizophrenia: a one-year follow-up study. Archives of General Psychiatry, 2002; 59: 1002-10
181. Van Oel, C.J.; Sitskoorn, M.M.; Cremer, M.P.M.; Kahn, R.S. Schoolperformance as a premorbid marker for schizophrenia: a twin study. Schizophrenia Bulletin, 2002; 28: 401-414
182. Schutter DJ, Van Honk J, Koppeschaar H, Kahn R. Cortisol and reduced interhemispheric coupling between the left prefrontal and the right parietal cortex. J Neuropsychiatry Clin Neurosci. 2002 Winter;14(1):89-90.
183. Sommer IE, Ramsey NF, Mandl RC, Kahn RS. Language lateralization in monozygotic twin pairs concordant and discordant for handedness. Brain. 2002; 125: 2710-8
184. Sommer, I.E.C., Ramsey, N.F., Mandl, R.C.W., Kahn, R.S. Language lateralization in female patients with schizophrenia: an fMRI study. Schizophrenia Research, 2003; 60: 183-190
185. Keizer AM, Hijman R, van Dijk D, Kalkman CJ, Kahn RS. Cognitive self-assessment one year after on-pump and off-pump coronary artery bypass grafting. Annals of Thoracic Surgery. 2003; 75: 835-8; discussion 838-9

186. Posthuma D, Baare WF, Hulshoff Pol HE, Kahn RS, Boomsma DI, De Geus EJ. Genetic Correlations Between Brain Volumes and the WAIS-III Dimensions of Verbal Comprehension, Working Memory, Perceptual Organization, and Processing Speed. Twin Research. 2003; 6: 131-9
187. Terpstra, J.; Gispens-de Wied, C.C.; Broekhoven, M.H.; Frankhuijzen, A.C.; Kahn, R.S.; van Ree, JM.; Wiegant, V.M. Attenuated stress responsiveness in an animal model for neurodevelopmental psychopathological disorders. European Neuropsychopharmacology 2003; 13: 249-256
188. Sommer IE, Aleman A, Kahn RS. Left with the voices or hearing right? Lateralization of auditory verbal hallucinations in schizophrenia. Journal of Psychiatry and Neuroscience. 2003; 28: 217-8
189. Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Archives of General Psychiatry. 2003; 60: 565-71
190. van Meijel B, van der Gaag M, Kahn RS, Grypdonck MH. Relapse prevention in patients with schizophrenia. Archives of Psychiatric Nursing. 2003; 17: 117-25
191. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM; HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry. 2003; 160:1396-404
192. Selten JP, Cantor-Graae E, Nahon D, Levav I, Aleman A, Kahn RS. No relationship between risk of schizophrenia and prenatal exposure to stress during the Six-Day War or Yom Kippur War in Israel. Schizophrenia Research. 2003; 63: 131-5
193. Kromkamp M, Uylings HB, Smidt MP, Hellemons AJ, Burbach JP, Kahn RS. Decreased thalamic expression of the homeobox gene DLX1 in psychosis. Archives of General Psychiatry. 2003; 60: 869-74
194. Sommer IEC, Kahn RS. The left hemisphere as the redundant hemisphere. Behavioral and Brain Sciences. 2003 Apr; 26(2):239+
195. van Meijel B, van der Gaag M, Kahn RS, Grypdonck MH. Relapse prevention in patients with schizophrenia: the application of an intervention protocol in nursing practice. Archives of Psychiatric Nursing. 2003; 17: 165-72
196. Appels MCM, Sitskoorn MM, Westers P, Lems E, Kahn RS. Cognitive dysfunctions in parents of schizophrenic patients parallel the deficits found in patients. Schizophrenia Research. 2003; 63: 285-293
197. van Haren NE, Cahn W, Hulshoff Pol HE, Schnack HG, Caspers E, Lemstra A, Sitskoorn MM, Wiersma D, van den Bosch RJ, Dingemans PM, Schene AH, Kahn RS. Brain volumes as predictor of outcome in recent-onset schizophrenia: a multi-center MRI study. Schizophrenia Research. 2003; 64: 41-52
198. Lampe IK, Hulshoff Pol HE, Janssen J, Schnack HG, Kahn RS, Heeren TJ. Association of depression duration with reduction of global cerebral gray matter volume in female patients with recurrent major depressive disorder. Am J Psychiatry. 2003; 160: 2052-4.

199. Hijman R, Hulshoff Pol HE, Sitskoorn MM, Kahn RS. Global intellectual impairment does not accelerate with age in patients with schizophrenia: a cross-sectional analysis. Schizophr Bull, 2003; 29: 509-17.
200. Aleman A, Bocker KB, Hijman R, de Haan EH, Kahn RS. Cognitive basis of hallucinations in schizophrenia: role of top-down information processing. Schizophr Res, 2003; 64: 175-85.
201. van der Wee NJ, Ramsey NF, Jansma JM, Denys DA, van Megen HJ, Westenberg HM, Kahn RS. Spatial working memory deficits in obsessive compulsive disorder are associated with excessive engagement of the medial frontal cortex. Neuroimage, 2003; 20: 2271-80.
202. Aleman A, Kahn RS. Aripiprazol: een nieuw en veelbelovend antipsychoticum. Ned Tijdschr Geneesk, 2003; 147: 2192-2193
203. Ramsey NF, Jansma JM, Jager G, Raalten TV, Kahn RS. Neurophysiological factors in human information processing capacity. Brain, 2003; 127:5167-25
204. Hulshoff Pol HE, Brans RG, van Haren NE, Schnack HG, Langen M, Baare WF, van Oel CJ, Kahn RS. Gray and white matter volume abnormalities in monozygotic and same-gender dizygotic twins discordant for schizophrenia, Biol Psychiatry, 2004; 55: 126-30.
205. Hulshoff Pol HE, Schnack HG, Mandl RCW, Cahn W, Collins L, Evans AC, Kahn RS. Focal white matter density changes in schizophrenia: reduced inter-hemispheric connectivity. NeuroImage 2004; 21: 27-35
206. Cahn W, Hulshoff Pol HE, Caspers E, van Haren NE, Schnack HG, Kahn RS. Cannabis and brain morphology in recent-onset schizophrenia. Schizophr Res. 2004 Apr 1;67(2-3):305-7
207. Sommer IE, Ramsey NF, Mandl RC, van Oel CJ, Kahn RS. Language activation in monozygotic twins discordant for schizophrenia. Br J Psychiatry. 2004 Feb;184:128-35
208. Veen ND, Selten JP, Van der Tweel I, Feller WG, Hoek HW, Kahn RS. Cannabis Use and Age at Onset of Schizophrenia, Am J Psychiatry 2004; 161:501-506
209. Van der Heijden FMMA, Tuinier S, Fekkes D, Sijben AES, Kahn RS, Verhoeven WMA. Atypical antipsychotics and the relevance of glutamate and serotonin, European Neuropsychopharmacology 2004; 14:259-265
210. Jansma JM, Ramsey NF, van der Wee NJ, Kahn RS. Working memory capacity in schizophrenia: a parametric fMRI study. Schizophr Res. 2004 Jun 1;68(2-3):159-71
211. Durston S, Hulshoff Pol HE, Schnack HG, Buitelaar JK, Steenhuis MP, Minderaa RB, Kahn RS, van Engeland H. Magnetic resonance imaging of boys with attention-deficit/hyperactivity disorder and their unaffected siblings. J Am Acad Child Adolesc Psychiatry. 2004 Mar;43(3):332-40.
212. Baas D, Aleman A, Kahn RS. Lateralization of amygdala activation: a systematic review of functional neuroimaging studies. Brain Res Brain Res Rev. 2004 May;45(2):96-103

213. Van 't Wout M, Aleman A, Kessels RPC, Larøi F, Kahn RS. Emotional processing in a non-clinical psychosis-prone sample, Schizophrenia Research 2004; 68:271-281
214. Schnack HG, Van Haren NEM, Hulshoff Pol HE, Picchioni M, Weisbrod M, Sauer H, Cannon T, Huttunen M, Murray R, Kahn RS. Reliability of brain volumes from multicenter MRI acquisition: a calibration study. Human Brain Mapping 2004; 22:312-320
215. Sommer IEC, Aleman A, Bouma A, Kahn RS. Do women really have more bilateral language representation than men ? A meta-analysis of functional imaging studies, Brain 2004 Aug;127, 1-8
216. Perkins D, Lieberman J, Gu H, Tohen M, McEvoy J, Green A, Zipursky R, Strakowski S, Sharma T, Kahn R, Gur R, Tollefson G. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2004; 185:18-24
217. Oranje B, Kahn RS, Kemner C, Verbaten MN. Modulating sensorimotor gating in healthy volunteers: the effects of desipramine and haloperidol. Psychiatry Research 2004; 127:195-205
218. Veen ND, Selten JP, Schols D, Laan W, Hoek HW, Tweel I van der, Kahn RS. Diagnostic stability in a Dutch psychosis incidence cohort. British Journal of Psychiatry 2004; 185:460-464
219. Wee NJ van der, Stevens H, Hardeman JA, Mandl RC, Denys DA, Megen HJ van, Kahn RS, Westenberg HM. Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [¹²³I]β-CIT SPECT. Am J Psychiatry 2004; 161:2201-2206
220. van der Heijden FM, Tuinier S, Kahn RS, Verhoeven WM. Nonschizophrenic psychotic disorders: the case of cycloid psychoses. Psychopathology. 2004 Jul-Aug;37(4):161-7
221. Kahn RS, Brandt D, Whitaker RC. Combined effect of mothers' and fathers' mental health symptoms on children's behavioral and emotional well-being. Arch Pediatr Adolesc Med. 2004 Aug;158(8):721-9
222. Sitskoorn MM, Ebisch SJ, Appels M, Nuyen J, Kahn RS. Memory profiles in parents of patients with schizophrenia. Psychiatry Res. 2004 Aug 30;128(1):27-37
223. van Meijel, van der Gaag M, Kahn R, Grypdonck M. [Intervention protocol for preventing psychotic recurrence: detecting warning signs early] Pflege Z. 2004 Aug;57(8):563-7. German.
224. van Haren NE, Picchioni MM, McDonald C, Marshall N, Davis N, Ribchester T, Hulshoff Pol HE, Sharma T, Sham P, Kahn RS, Murray R. A controlled study of brain structure in monozygotic twins concordant and discordant for schizophrenia. Biol Psychiatry. 2004 Sep 15;56(6):454-61
225. Oranje B, Gispens-de Wied CC, Westenberg HG, Kemner C, Verbaten MN, Kahn RS. Increasing dopaminergic activity: effects of L-dopa and bromocriptine on human sensory gating. J Psychopharmacol. 2004 Sep;18(3):388-94

226. van Meijel B, van der Gaag M, Kahn RS, Grypdonck MH. Recognition of early warning signs in patients with schizophrenia: a review of the literature. Int J Ment Health Nurs. 2004 Jun;13(2):107-16
227. Schnack HG, Bakker SC, van 't Slot R, Groot BM, Sinke RJ, Kahn RS, Pearson PL. Accurate determination of microsatellite allele frequencies in pooled DNA samples. Eur J Hum Genet. 2004 Nov;12(11):925-34
228. Appels MC, Sitskoorn MM, Vollema MG, Kahn RS. Elevated levels of schizotypal features in parents of patients with a family history of schizophrenia spectrum disorders. Schizophr Bull. 2004;30(4):781-90.
229. Palmén SJ, Pol HE, Kemner C, Schnack HG, Janssen J, Kahn RS, van Engeland H. Larger brains in medication naive high-functioning subjects with pervasive developmental disorder. J Autism Dev Disord. 2004 Dec;34(6):603-13
230. Bakker SC, Hoogendoorn ML, Selten JP, Verdúijn W, Pearson PL, Sinke RJ, Kahn RS. Neuregulin 1: genetic support for schizophrenia subtypes. Mol Psychiatry. 2004 Dec;9(12):1061-3
231. Sitskoorn MM, Aleman A, Ebisch SJ, Appels MC, Kahn RS. Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophr Res. 2004 Dec 1;71(2-3):285-95
232. Janssen J, Hulshoff Pol HE, Lampe IK, Schnack HG, de Leeuw FE, Kahn RS, Heeren TJ. Hippocampal changes and white matter lesions in early-onset depression. Biol Psychiatry. 2004 Dec 1;56(11):825-31
233. Aleman A, de Haan EHF, Kahn RS. Underconstrained perception or underconstrained theory? Behavioral and Brain Sciences. 2004 dec;27(6):787+
234. Aleman A, Kahn RS. Genes can disconnect the social brain in more than one way. Behavioral and Brain Sciences. 2004 dec;27(6):855+
235. Selten JP, Zeyl C, Dwarkasing R, Lumsden V, Kahn RS, Van Harten PN. First-contact incidence of schizophrenia in Surinam. Br J Psychiatry. 2005 Jan;186:74-5
236. Hoogendoorn MLC, Bakker SC, Schnack HG, Selten JP, Otten HG, Verdúijn W, van der Heijden FM, Pearson PL, Kahn RS, Sinke RJ. No association between 12 dopaminergic genes and schizophrenia in a large Dutch sample. Am J Med Genet B Neuropsychiatr Genet. 2005 134B(1): 6-9
237. Aleman A, de Haan EH, Kahn RS. Object versus spatial visual mental imagery in patients with schizophrenia. J Psychiatry Neurosci. 2005 Jan;30(1):53-6
238. Van der Heijden FM, Tuinier S, Arts NJ, Hoogendoorn ML, Kahn RS, Verhoeven WM. Catatonia: disappeared or under-diagnosed? Psychopathology. 2005 Jan-Feb;38(1):3-8
239. Veen ND, Selten JP, Kahn RS. Cannabis use and schizophrenia – Reply. American Journal of Psychiatry. 2005 feb;162(2):402-402

240. Aleman A, Formisano E, Koppenhagen H, Hagoort P, de Haan EH, Kahn RS. The functional neuroanatomy of metrical stress evaluation of perceived and imagined spoken words. Cereb Cortex. 2005 Feb;15(2):221-8
241. Durston S, Fossella JA, Casey BJ, Hulshoff Pol HE, Galvan A, Schnack HG, Steenhuis MP, Minderaa RB, Buitelaar JK, Kahn RS, van Engeland H. Differential effects of DRD4 and DAT1 genotype on fronto-striatal gray matter volumes in a sample of subjects with attention deficit hyperactivity disorder, their unaffected siblings, and controls. Mol Psychiatry. 2005 10(7):678-685
242. Nuyen J, Sitskoorn MM, Cahn W, Kahn RS. Verbal memory in first-episode schizophrenia: heterogeneity in performance? J Int Neuropsychol Soc. 2005 Mar;11(2):152-62.
243. Van Der Heijden FM, Fekkes D, Tuinier S, Sijben AE, Kahn RS, Verhoeven WM. Amino acids in schizophrenia: evidence for lower tryptophan availability during treatment with atypical antipsychotics? J Neural Transm. 2005 Apr;112(4): 577-85
244. Muntjewerff JW, Hoogendoorn ML, Kahn RS, Sinke RJ, Den Heijer M, Kluijtmans LA, Blom HJ. Hyperhomocysteinemia, methylenetetrahydrofolate reductase 677TT genotype, and the risk for schizophrenia: a Dutch population based case-control study. Am J Med Genet B Neuropsychiatr Genet. 2005 May 5;135(1):69-72.
245. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M; HGDH Study Group. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005 Apr;62(4):361-70.
246. Van Rijn S, Aleman A, Swaab H, Kahn RS. Neurobiology of emotion and high risk for schizophrenia: role of the amygdala and the X-chromosome. Neurosci Biobehav Rev. 2005 May;29(3):385-97.
247. De Bruin EA, Pol HE, Bijl S, Schnack HG, Fluitman S, Bocker KB, Kenemans JL, Kahn RS, Verbaten MN. Associations between alcohol intake and brain volumes in male and female moderate drinkers. Alcohol Clin Exp Res. 2005 Apr;29(4):656-63.
248. Vink M, Kahn RS, Raemaekers M, Ramsey NF. Perceptual bias following visual target selection. Neuroimage. 2005 May 1;25(4):1168-74.
249. Palmén SJ, Hulshoff Pol HE, Kemner C, Schnack HG, Durston S, Lohuis BE, Kahn RS, Van Engeland H. Increased gray-matter volume in medication-naive high-functioning children with autism spectrum disorder. Psychol Med. 2005 Apr;35(4):561-70.
250. Patino LR, Selten JP, Van Engeland H, Duijckx H, Kahn RS, Burger H. Migration, family dysfunction and psychotic symptoms in children and adolescents. Br J Psychiatry. 2005 May;186:442-3.
251. Sommer IEC, Kahn RS. Language lateralization in schizophrenia – Reply. British Journal of Psychiatry. 2005;186:444-445

252. Sommer I, Aleman A, Kahn RS. Reply to 'Time-resolved sex differences in language lateralization. Brain. 2005 May;128(5):E29
253. Sommer I, Aleman A, Kahn RS. Size does count: a reply to Kitazawa and Kansaku. Brain. 2005 May;128(5):E31
254. De Bruin EA, Hulshoff Pol HE, Schnack HG, Janssen J, Bijl S, Evans AC, Leon Kenemans J, Kahn RS, Verbaten MN. Focal brain matter differences associated with lifetime alcohol intake and visual attention in male but not in female non-alcohol-dependent drinkers. Neuroimage. 2005 Jun 1;26(2):536-45.
255. de Krom M, Bakker SC, Hendriks J, van Elburg A, Hoogendoorn M, Verduyn W, Sinke R, Kahn R, Adan RA. Polymorphisms in the brain-derived neurotrophic factor gene are not associated with either anorexia nervosa or schizophrenia in Dutch patients. Psychiatr Genet. 2005 Jun;15(2):81.
256. Vink M, Kahn RS, Raemaekers M, van den Heuvel M, Boersma M, Ramsey NF. Function of striatum beyond inhibition and execution of motor responses. Hum Brain Mapp. 2005 Jul;25(3):336-44.
257. Raemaekers M, Vink M, van den Heuvel MP, Kahn RS, Ramsey NF. Brain activation related to retrosaccades in saccade experiments. Neuroreport. 2005 Jul 13;16(10):1043-7.
258. van Rijn S, Aleman A, van Diessen E, Berckmoes C, Vingerhoets G, Kahn RS. What is said or how it is said makes a difference: role of the right fronto-parietal operculum in emotional prosody as revealed by repetitive TMS. Eur J Neurosci. 2005 Jun;21(11):3195-3200.
259. Fleischhacker WW, Keet IP, Kahn RS; EUFEST Steering Committee. The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial. Schizophr Res. 2005 Oct 15;78(2-3):147-56.
260. Scholten MR, Aleman A, Montagne B, Kahn RS. Schizophrenia and processing of facial emotions: sex matters. Schizophr Res. 2005 Oct 1;78(1):61-7.
261. Keizer AM, Hijman R, Kalkman CJ, Kahn RS, van Dijk D; (on behalf of the Octopus Study Group). The incidence of cognitive decline after (not) undergoing coronary artery bypass grafting: the impact of a controlled definition. Acta Anaesthesiol Scand. 2005 Oct;49(9):1232-5.
262. Rijdsdijk FV, van Haren NE, Picchioni MM, McDonald C, Touloupoulou T, Pol HE, Kahn RS, Murray R, Sham PC. Brain MRI abnormalities in schizophrenia: same genes or same environment? Psychol Med. 2005 Oct;35(10):1399-409
263. Schutter DJ, Peper JS, Koppeschaar HP, Kahn RS, van Honk J. Administration of testosterone increases functional connectivity in a cortico-cortical depression circuit. J Neuropsychiatry Clin Neurosci. 2005 Summer;17(3):372-7
264. Palmén SJ, Hulshoff Pol HE, Kemner C, Schnack HG, Sitskoorn MM, Appels MC, Kahn RS, Van Engeland H. Brain anatomy in non-affected parents of autistic probands: a MRI study. Psychol Med. 2005 Oct;35(10):1411-20

265. Vink M, Ramsey NF, Raemaekers M, Kahn RS. Negative priming in schizophrenia revisited. Schizophrenia Research. 2005 nov 15; 79(2-3):211-6. Epub 2005, jun 22
266. van 't Wout M, Kahn RS, Sanfey AG, Aleman AI. Repetitive transcranial magnetic stimulation over the right dorsolateral prefrontal cortex affects strategic decision-making. Neuroreport. 2005 nov; 16(16):1849-52
267. Raemaekers M, Ramsey NF, Vink M, van den Heuvel MP, Kahn RS. Brain Activation During Antisaccades in Unaffected Relatives of Schizophrenic Patients. Biol Psychiatry. 2006 59(6). 530-535
268. Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry. 2006 11(2), 143-149
269. Sommer IEC, Oranje B, Ramsey NF, Klerk FA, Mandl RC, Westenberg HG, Kahn RS. The influence of amphetamine on language activation: an fMRI study. Psychopharmacology. 2006 jan,183(4):387-93
270. Aleman A, Kahn RS. Strange feelings: Do amygdala abnormalities dysregulate the emotional brain in schizophrenia? Prog Neurobiol. 2005 Dec;77(5):283-98
271. Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, Strakowski SM, Sharma T, Kahn RS, Gur RE, Tollefson GD, Lieberman JA. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005 Dec;187:537-43
272. Oranje B, Gispens-De Wied CC, Westenberg HG, Kemner C, Verbaten MN, Kahn RS. No effects of l-dopa and bromocriptine on psychophysiological parameters of human selective attention. J Psychopharmacol. 2006, 20, 789-798
273. Hulshoff Pol HE, Schnack HG, Mandl RC, Brans RG, van Haren NE, Baare WF, van Oel CJ, Collins DL, Evans AC, Kahn RS. Gray and white matter density changes in monozygotic and same-sex dizygotic twins discordant for schizophrenia using voxel-based morphometry. Neuroimage. 2006 Feb; 31(2), 482-488
274. van 't Wout M, Kahn RS, Sanfey AG, Aleman A. Affective state and decision-making in the Ultimatum Game. Exp Brain Res. 2006 Mar;169(4):564-8
275. Appels, M.C.M., Sitskoorn, M.M., Westers, P., Lems, E., & Kahn, R.S. (2006). Cognitive dysfunctions in parents of schizophrenic patients parallel the deficits found in patients. Schizophrenia Research, 63(3), 285-299
276. Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrino F, Green AI, Glick IB, Kahn RS, Sharma T, Tohen M, McEvoy JP, Weiden PJ, Lieberman JA; HGDH Research Group. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006 Mar 1;83(1):53-63

277. Jager G, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology (Berl). 2006 Apr;185(3):358-68
278. van Meijel B, Kruitwagen C, van der Gaag M, Kahn RS, Grypdonck MH. An intervention study to prevent relapse in patients with schizophrenia. J Nurs Scholarsh. 2006;38(1):42-9
279. Vink M, Ramsey NF, Raemaekers M, Kahn RS.. Striatal dysfunction in schizophrenia and unaffected relatives. Biol Psychiatry. 2006 Jul 1;60(1):32-9.
280. van Rijn S, Swaab H, Aleman A, Kahn RS. X Chromosomal effects on social cognitive processing and emotion regulation: A study with Klinefelter men (47,XXY). Schizophr Res. 2006 Jun;84(2-3):194-203
281. Scholten MR, van Honk J, Aleman A, Kahn RS. Behavioral inhibition system (BIS), Behavioral activation system (BAS) and schizophrenia: Relationship with psychopathology and physiology. J Psychiatr Res. 2006 Apr; 40(7), 638-645
282. van der Wee NJ, Hardeman HH, Ramsey NF, Raemaekers M, VAN Megen HJ, Denys DA, Westenberg HG, Kahn RS. Saccadic abnormalities in psychotropic-naïve obsessive-compulsive disorder without co-morbidity. Psychol Med. 2006 Sep;36(9):1321-6
283. Raemaekers M, Vink M, van den Heuvel MP, Kahn RS, Ramsey NF. Effects of aging on BOLD fMRI during prosaccades and antisaccades. J Cogn Neurosci. 2006 Apr;18(4):594-603
284. Kahn, R.S. (2006). Foreword. European Neuropsychopharmacology, 16(suppl.3)
285. Rijn, S. van, Aleman, A., Swaab-Barneveld, J.T., & Kahn, R.S. Klinefelter's syndrome (karyotype 47,XXY) and schizophrenia-spectrum pathology. British Journal of Psychiatry, 2006 189(Nov), 459-460
286. van der Wee NJ, Ramsey NF, van Megen HJ, Denys D, Westenberg HG, Kahn RS. Spatial working memory in obsessive-compulsive disorder improves with clinical response: A functional MRI study. Eur Neuropsychopharmacol. 2007 Jan;17(1):16-23. Epub 2006 Jun 21
287. Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB; The HGDH Study Group. Olanzapine and haloperidol in first episode psychosis: Two-year data. Schizophr Res. 2006, 86(1-3), 234-243
288. Vorstman JA, Morcus ME, Duijff SN, Klaassen PW, Heineman-de Boer JA, Beemer FA, Swaab H, Kahn RS, van Engeland H. The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms. J Am Acad Child Adolesc Psychiatry. 2006 Sep;45(9):1104-13
289. Cahn W, van Haren NE, Hulshoff Pol HE, Schnack HG, Caspers E, Laponder DA, Kahn RS. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. Br J Psychiatry. 2006 Oct;189:381-2

290. Hulshoff Pol HE, Schnack HG, Posthuma D, Mandl RC, Baare WF, van Oel C, van Haren NE, Collins DL, Evans AC, Amunts K, Burgel U, Zilles K, de Geus E, Boomsma DI, Kahn RS. Genetic contributions to human brain morphology and intelligence. J Neurosci. 2006 Oct 4;26(40):10235-42
291. Sommer IE, Vd Veer AJ, Wijkstra J, Boks MP, Kahn RS. Comparing language lateralization in psychotic mania and psychotic depression to schizophrenia; A functional MRI study. Schizophr Res. 2007 Jan;89(1-3):364-5. Epub 2006 Oct 20
292. Laan W, Selten JP, Grobbee De, Smeets H, Kahn RS, Burger H. Non-steroidal anti-inflammatory drugs and the risk of psychosis. European Neuropsychopharmacology. 2007, 17: 309-311
293. Laan W, Selten JP, Kahn RS, Huisman AM, Heijnen CJ, Grobbee DE, Burger H. Acetylsalicylic acid as an adjuvant therapy for schizophrenia. Trials. 2006 Oct 23;7:31
294. Hulshoff Pol HE, Cohen-Kettenis PT, Van Haren NE, Peper JS, Brans RG, Cahn W, Schnack HG, Gooren LJ, Kahn RS. Changing your sex changes your brain: influences of testosterone and estrogen on adult human brain structure. Eur J Endocrinol. 2006 Nov;155 Suppl 1:S107-14
295. Jager G, Van Hell HH, De Win MM, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF. Effects of frequent cannabis use on hippocampal activity during an associative memory task. Eur Neuropsychopharmacol. 2007 Mar;17(4):289-97
296. Holthausen EA, Wiersma D, Cahn W, Kahn RS, Dingemans PM, Schene AH, van den Bosch RJ. Predictive value of cognition for different domains of outcome in recent-onset schizophrenia. Psychiatry Res. 2007 Jan 15;149(1-3):71-80
297. Vonk R, van der Schot AC, Kahn RS, Nolen WA, Drexhage HA. Is Autoimmune Thyroiditis Part of the Genetic Vulnerability (or an Endophenotype) for Bipolar Disorder? Biol Psychiatry. 2007 Jul 15;62(2):135-140
298. Van 't Wout M, Aleman A, Bermond B, Kahn RS. No words for feelings: alexithymia in schizophrenia patients and first-degree relatives. Compr Psychiatry. 2007 Jan-Feb;48(1):27-33
299. Janssen J, Hulshoff Pol HE, de Leeuw FE, Schnack HG, Lampe IK, Kok RM, Kahn RS, Heeren TJ. Hippocampal volume and subcortical white matter lesions in late life depression: comparison of early and late onset depression. J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):638-40
300. Boks MP, Rietkerk T, van de Beek MH, Sommer IE, de Koning TJ, Kahn RS. Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia. Eur Neuropsychopharmacol. 2007 Jan 22;17:567-572
301. Selten JP, Cantor-Graae E, Kahn RS. Migration and schizophrenia. Curr Opin Psychiatry. 2007 Mar;20(2):111-5. Review
302. Van 't Wout M, Aleman A, Kessels RP, Cahn W, de Haan EH, Kahn RS. Exploring the nature of facial affect processing deficits in schizophrenia. Psychiatry Res. 2007 Apr 15;150(3):227-35

303. Van Haren NE, Hulshoff Pol HE, Schnack HG, Cahn W, Mandl RC, Collins DL, Evans AC, Kahn RS. Focal Gray Matter Changes in Schizophrenia across the Course of the Illness: A 5-Year Follow-Up Study. Neuropsychopharmacology. 2007 Oct;32(10):2057-66
304. Boos HB, Aleman A, Cahn W, Pol HH, Kahn RS. Brain volumes in relatives of patients with schizophrenia: a meta-analysis. Arch Gen Psychiatry. 2007 Mar;64(3):297-304.
305. Van 't Wout M, Aleman A, Kessels RP, Kahn RS. Object-location memory in schizophrenia: interference of symbolic threatening content. Cognit Neuropsychiatry. 2006 May;11(3):272-84. Review
306. Janssen J, Pol HE, Schnack HG, Kok RM, Lampe IK, de Leeuw FE, Kahn RS, Heeren TJ. Cerebral volume measurements and subcortical white matter lesions and short-term treatment response in late life depression. Int J Geriatr Psychiatry. 2007 May;22(5):468-74
307. Aleman A, Sommer IE, Kahn RS. Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis. J Clin Psychiatry. 2007 Mar;68(3):416-21
308. Boks MP, Leask S, Vermunt JK, Kahn RS. The structure of psychosis revisited: The role of mood symptoms. Schizophr Res. 2007 Jul;93(1-3):178-85
309. Bakker SC, Hoogendoorn ML, Hendriks J, Verzijlbergen K, Caron S, Verduijn W, Selten JP, Pearson PL, Kahn RS, Sinke RJ. The PIP5K2A and RGS4 genes are differentially associated with deficit and non-deficit schizophrenia. Genes Brain Behav. 2007 Mar;6(2):113-9
310. Peper JS, Brouwer RM, Boomsma DI, Kahn RS, Hulshoff Pol HE. Genetic influences on human brain structure: a review of brain imaging studies in twins. Hum Brain Mapp. 2007 Jun;28(6):464-73
311. Boks MP, de Vette MH, Sommer IE, van Rijn S, Giltay JC, Swaab H, Kahn RS. Psychiatric morbidity and X-chromosomal origin in a Klinefelter sample. Schizophr Res. 2007 Jul;93(1-3):399-402
312. Jager G, de Win MM, van der Tweel I, Schilt T, Kahn RS, van den Brink W, van Ree JM, Ramsey NF. Assessment of Cognitive Brain Function in Ecstasy Users and Contributions of Other Drugs of Abuse: Results from an fMRI Study. Neuropsychopharmacology. 2008, 33(2), 247-258
313. Jager G, de Win MM, Vervaeke HK, Schilt T, Kahn RS, van den Brink W, van Ree JM, Ramsey NF. Incidental use of ecstasy: no evidence for harmful effects on cognitive brain function in a prospective fMRI study. Psychopharmacology (Berl). 2007 Aug;193(3):403-14
314. van Os J, Kahn R. Remission criteria in schizophrenia. Tijdschr Psychiatr. 2007;49(1):21-6
315. Sommer IE, Slotema CW, de Weijer AD, Blom JD, Daalman K, Neggers SF, Somers M, Hoek HW, Aleman A, Kahn RS. Can fMRI-guidance improve the efficacy of rTMS treatment for auditory verbal hallucinations? Schizophr Res. 2007 Jul;93(1-3):406-8

316. Raemaekers M, Vink M, Zandbelt B, van Wezel RJ, Kahn RS, Ramsey NF. Test-retest reliability of fMRI activation during prosaccades and antisaccades. Neuroimage. 2007 Jul 1;36(3):532-42
317. Muntjewerff JW, Hoogendoorn ML, Aukes MF, Kahn RS, Sinke RJ, Blom HJ, Heijer MD. No evidence for a preferential transmission of the methylenetetrahydrofolate reductase 677T allele in families with schizophrenia offspring. Am J Med Genet B Neuropsychiatr Genet. 2007 Oct 5;144B(7):891-4
318. Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O, Andersson HM, Meulien D; Study 132 Investigators. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007 Jun;68(6):832-42
319. Van Haren NE, Pol HE, Schnack HG, Cahn W, Brans R, Carati I, Rais M, Kahn RS. Progressive Brain Volume Loss in Schizophrenia Over the Course of the Illness: Evidence of Maturational Abnormalities in Early Adulthood. Biol Psychiatry. 2008, 63(1), 106-113
320. Friedman JI, Vrijenhoek T, Markx S, Janssen IM, van der Vliet WA, Faas BH, Knoers NV, Cahn W, Kahn RS, Edelmann L, Davis KL, Silverman JM, Brunner HG, van Kessel AG, Wijmenga C, Ophoff RA, Veltman JA. CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy. Mol Psychiatry. 2008 Mar;13(3):261-6
321. Selten JP, Veen ND, Hoek HW, Laan W, Schols D, van der Tweel I, Feller W, Kahn RS. Early course of schizophrenia in a representative Dutch incidence cohort. Schizophr Res. 2007 Dec;97(1-3):79-87
322. Muntjewerff JW, Gellekink H, den Heijer M, Hoogendoorn ML, Kahn RS, Sinke RJ, Blom HJ. Polymorphisms in catechol-O-methyltransferase and methylenetetrahydrofolate reductase in relation to the risk of schizophrenia. Eur Neuropsychopharmacol. 2008 Feb;18(2):99-106
323. Hoekert M, Kahn RS, Pijnenborg M, Aleman A. Impaired recognition and expression of emotional prosody in schizophrenia: Review and meta-analysis. Schizophr Res. 2007 Nov;96(1-3):133-45
324. Jungerius BJ, Hoogendoorn ML, Bakker SC, Van't Slot R, Bardoel AF, Ophoff RA, Wijmenga C, Kahn RS, Sinke RJ. An association screen of myelin-related genes implicates the chromosome 22q11 PIK4CA gene in schizophrenia. Mol Psychiatry. 2008 nov;13(11):1060-8
325. van Rijn S, Aleman A, Swaab H, Krijn T, Vingerhoets G, Kahn RS. What it is said versus how it is said: Comprehension of affective prosody in men with Klinefelter (47,XXY) syndrome. J Int Neuropsychol Soc. 2007 Nov;13(6):1065-1070
326. Jungerius BJ, Bakker SC, Monsuur AJ, Sinke RJ, Kahn RS, Wijmenga C. Is MYO9B the missing link between schizophrenia and celiac disease? Am J Med Genet B Neuropsychiatr Genet. 2008 Apr 5;147(3):351-5
327. Scholten MR, Aleman A, Kahn RS. The processing of emotional prosody and semantics in schizophrenia: relationship to gender and IQ. Psychol Med. 2008 38(6), 887-898

328. Rosa A, Picchioni MM, Kalidindi S, Loat CS, Knight J, Toulopoulou T, Vonk R, van der Schot AC, Nolen W, Kahn RS, McGuffin P, Murray RM, Craig IW. Differential methylation of the X-chromosome is a possible source of discordance for bipolar disorder female monozygotic twins. Am J Med Genet B Neuropsychiatr Genet. 2008 Jan;98(1-3):84-8
329. Aleman A, Sommer IE, Kahn R. Review: Slow repetitive transcranial magnetic stimulation reduces auditory hallucinations in people with schizophrenia. Evid Based Ment Health. 2007 Nov;10(4):114
330. Hoogendoorn ML, Vorstman JA, Jalali GR, Selten JP, Sinke RJ, Emanuel BS, Kahn RS. Prevalence of 22q11.2 deletions in 311 Dutch patients with schizophrenia. Schizophr Res. 2008 Jan;98(1-3):84-8
331. Boks MP, Schipper M, Schubart CD, Sommer IE, Kahn RS, Ophoff RA. Investigating gene environment interaction in complex diseases: increasing power by selective sampling for environmental exposure. Int J Epidemiol. 2007 Dec;36(6):1363-9
332. Van't Wout M, van Dijke A, Aleman A, Kessels RP, Pijpers W, Kahn RS. Fearful faces in schizophrenia: the relationship between patient characteristics and facial affect recognition. J Nerv Ment Dis. 2007 Sep;195(9):758-64
333. Baas D, Van't Wout M, Aleman A, Kahn RS. Social judgement in clinically stable patients with schizophrenia and healthy relatives: behavioural evidence of social brain dysfunction. Psychol Med. 2008 May;38(5):747-54
334. Sommer IE, Cohen-Kettenis PT, van Raalten T, Vd Veer AJ, Ramsey LE, Gooren LJ, Kahn RS, Ramsey NF. Effects of cross-sex hormones on cerebral activation during language and mental rotation: An fMRI study in transsexuals. Eur Neuropsychopharmacol. 2008 18(3), 215-221
335. Zandi T, Havenaar JM, Limburg-Okken AG, van Es H, Sidali S, Kadri N, van den Brink W, Kahn RS. The need for culture sensitive diagnostic procedures : A study among psychotic patients in Morocco. Soc Psychiatry Psychiatr Epidemiol. 2008 Mar;43(3):244-50
336. van Raalten TR, Ramsey NF, Jansma JM, Jager G, Kahn RS. Automatization and working memory capacity in schizophrenia. Schizophr Res. 2008 Mar;100(1-3):161-71
337. Boks MP, Hoogendoorn M, Jungerius BJ, Bakker SC, Sommer IE, Sinke RJ, Ophoff RA, Kahn RS. Do mood symptoms subdivide the schizophrenia phenotype? association of the GMP6A gene with a depression subgroup. Am J Med Genet B Neuropsychiatr Genet. 2008 147(6), 7-7-711
338. Boos, HBM, Aleman A, Cahn W, Hulshoff Pol HE, Kahn RS. Meta-analysis of brain volumes in unaffected first-degree relatives of patients with schizophrenia overemphasizes hippocampal deficits: reply. Archives of General Psychiatry. 2008 65(5), 604-606
339. Sommer IE, Aleman A, Somers M, Boks MP, Kahn RS. Sex differences in handedness, asymmetry of the Planum Temporale and functional language lateralization. Brain Res. 2008 Apr 24;1206:76-88
340. Aukes MF, Alizadeh BZ, Sitskoorn MM, Selten JP, Sinke RJ, Kemner C, Ophoff RA, Kahn RS.

- Finding Suitable Phenotypes for Genetic Studies of Schizophrenia: Heritability and Segregation Analysis. Biol Psychiatry. 2008 Jul 15;64(2):128-36
341. van Rijn S, Aleman A, Swaab H, Vink M, Sommer I, Kahn RS. Effects of an extra X chromosome on language lateralization: An fMRI study with Klinefelter men (47,XXY). Schizophr Res. 2008 Apr;101(1-3):17-25
342. van Haren NE, Bakker SC, Kahn RS. Genes and structural brain imaging in schizophrenia. Curr Opin Psychiatry. 2008 Mar;21(2):161-7.
343. Arango C, Kahn R. Progressive brain changes in schizophrenia. Schizophr Bull. 2008 Mar;34(2):310-1
344. Rietkerk T, Boks MP, Sommer IE, Liddle PF, Ophoff RA, Kahn RS. The genetics of symptom dimensions of schizophrenia: Review and meta-analysis. Schizophr Res. 2008 Jul;102(1-3):197-205
345. van Rijn S, Swaab H, Aleman A, Kahn RS. Social Behavior and Autism Traits in a Sex Chromosomal Disorder: Klinefelter (47XXY) Syndrome. J Autism Dev Disord. 2008 Oct;38(9):1634-41
346. Hulshoff Pol HE, Kahn RS. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull. 2008 Mar;34(2):354-66
347. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindfors N, Riecher-Rössler A, Grobbee DE; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008 Mar 29;371(9618):1085-97
348. Kahn RS, Fleischhacker WW, Boter JP, Davidson M. Are all antipsychotics equal? – Authors' reply. Lancet. 2008 372(9634), 202-202
349. Baas D, Aleman A, Vink M, Ramsey NF, de Haan EH, Kahn RS. Evidence of altered cortical and amygdala activation during social decision-making in schizophrenia. Neuroimage. 2008 Apr 1;40(2):719-27
350. Koolschijn PC, van Haren NE, Hulshoff Pol HE, Kahn RS. Hypothalamus volume in twin pairs discordant for schizophrenia. Eur Neuropsychopharmacol. 2008 Apr;18(4):312-5
351. Rais M, Cahn W, Van Haren N, Schnack H, Caspers E, Hulshoff Pol H, Kahn RS. Excessive Brain Volume Loss Over Time in Cannabis-Using First-Episode Schizophrenia Patients. Am J Psychiatry. 2008 Apr;165(4):490-6
352. Fuchs SA, De Barse MM, Scheepers FE, Cahn W, Dorland L, de Sain-van der Velden MG, Klomp LW, Berger R, Kahn RS, de Koning TJ. Cerebrospinal fluid d-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients. Eur Neuropsychopharmacol. 2008 May;18(5):333-8

353. Hoekert M, Bais L, Kahn RS, Aleman A. Time course of the involvement of the right anterior superior temporal gyrus and the right fronto-parietal operculum in emotional prosody perception. PLoS ONE. 2008 May 21;3(5):e2244
354. van Haren NE, Cahn W, Hulshoff Pol HE, Kahn RS. Schizophrenia as a progressive brain disease. Eur Psychiatry. 2008 Jun;23(4):245-54
355. van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitmaker A, Caspers E, Luurtsema G, Windhorst AD, Cahn W, Lammertsma AA, Kahn RS. Microglia Activation in Recent-Onset Schizophrenia: A Quantitative (R)-[(11)C]PK11195 Positron Emission Tomography Study. Biol Psychiatry. 2008 Nov 1;64(9):820-2
356. Zandbelt BB, Gladwin TE, Raemaekers M, van Buuren M, Neggers SF, Kahn RS, Ramsey NF, Vink M. Within-subject variation in BOLD-fMRI signal changes across repeated measurements: quantification and implications for sample size. Neuroimage. 2008 Aug 1;42(1):196-206
357. Peper JS, Brouwer RM, Schnack HG, van Baal GC, van Leeuwen M, van den Berg SM, Delemarre-Van de Waal HA, Janke AL, Collins DL, Evans AC, Boomsma DI, Kahn RS, Pol HE. Cerebral white matter in early puberty is associated with luteinizing hormone concentrations. Psychoneuroendocrinology. 2008 Aug;33(7):909-15
358. Vorstman JA, Chow EW, Ophoff RA, van Engeland H, Beemer FA, Kahn RS, Sinke RJ, Bassett AS. Association of the PIK4CA schizophrenia-susceptibility gene in adults with the 22q11.2 deletion syndrome. Am J Med Genet B Neuropsychiatr Genet. 2009 Apr 5;150B(3):430-3
359. Stefansson H, Rujescu D, Cichon S, Pietiläinen OP, Ingason A, Steinberg S, Fossdal R, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, Hansen T, Jakobsen KD, Muglia P, Francks C, Matthews PM, Gylfason A, Halldorsson BV, Gudbjartsson D, Thorgeirsson TE, Sigurdsson A, Jonasdottir A, Jonasdottir A, Bjornsson A, Mattiasdottir S, Blondal T, Haraldsson M, Magnúsdóttir BB, Giegling I, Möller HJ, Hartmann A, Shianna KV, Ge D, Need AC, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Paunio T, Touloupoulou T, Bramon E, Di Forti M, Murray R, Ruggeri M, Vassos E, Tosato S, Walshe M, Li T, Vasilescu C, Mühleisen TW, Wang AG, Ullum H, Djurovic S, Melle I, Olesen J, Kiemeny LA, Franke B, Sabatti C, Freimer NB, Gulcher JR, Thorsteinsdottir U, Kong A, Andreassen OA, Ophoff RA, Georgi A, Rietschel M, Werge T, Petursson H, Goldstein DB, Nöthen MM, Peltonen L, Collier DA, St Clair D, Stefansson K, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I; Genetic Risk and Outcome in Psychosis (GROUP). Large recurrent microdeletions associated with schizophrenia. Nature. 2008 Sep 11;455(7210):232-6
360. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, van Gerven JM, Ramsey NF, Lammertsma AA, Kahn RS. Delta9-Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum. Neuropsychopharmacology. 2009 Feb;34(3):759-66
361. Vorstman JA, Turetsky BI, Sijmens-Morcus ME, de Sain MG, Dorland B, Sprong M, Rappaport EF, Beemer FA, Emanuel BS, Kahn RS, van Engeland H, Kemner C. Proline Affects Brain Function in 22q11DS Children with the Low Activity COMT(158) Allele. Neuropsychopharmacology. 2009 Feb;34(3):739-46

362. Sommer IE, Diederik KM, Blom JD, Willems A, Kushan L, Slotema K, Boks MP, Daalman K, Hoek HW, Niggers SF, Kahn RS. Auditory verbal hallucinations predominantly activate the right inferior frontal area. Brain. 2008 Dec131 (Pt 12): 3169-77
363. Vrijenhoek T, Buizer-Voskamp JE, van der Stelt I, Strengman E; Genetic Risk and Outcome in Psychosis (GROUP) Consortium, Sabatti C, Geurts van Kessel A, Brunner HG, Ophoff RA, Veltman JA. Recurrent CNVs disrupt three candidate genes in schizophrenia patients. Am J Hum Genet. 2008 Oct;83(4):504-10
364. Brans RG, van Haren NE, van Baal GC, Staal WG, Schnack HG, Kahn RS, Pol HE. Longitudinal MRI study in schizophrenia patients and their healthy siblings. Br J Psychiatry. 2008 Nov;193(5):422-3
365. Peper JS, Brouwer RM, Schnack HG, van Baal GC, van Leeuwen M, van den Berg SM, Delemarre-Van de Waal HA, Boomsma DI, Kahn RS, Hulshoff Pol HE. Sex steroids and brain structure in pubertal boys and girls. Psychoneuroendocrinology. 2009 Apr;34(3):332-42
366. Brans RG, van Haren NE, van Baal GC, Schnack HG, Kahn RS, Pol HE. Heritability of changes in brain volume over time in twin pairs discordant for schizophrenia. Arch Gen Psychiatry. 2008 Nov;65(11):1259-68
367. Mandl RC, Schnack HG, Zwiers MP, van der Schaaf A, Kahn RS, Hulshoff Pol HE. Functional diffusion tensor imaging: measuring task-related fractional anisotropy changes in the human brain along white matter tracts. PLoS ONE. 2008;3(11):e3631
368. Koning JP, Tenback DE, van Os J, Aleman A, Kahn RS, van Harten PN. Dyskinesia and Parkinsonism in Antipsychotic-Naive Patients With Schizophrenia, First-Degree Relatives and Healthy Controls: A Meta-analysis. Schizophr Bull. 2008 Nov 5 [Epub ahead of print]
369. Grootens KP, Vermeeren L, Jan Verkes R, Buitelaar JK, Sabbe BG, van Veelen N, Kahn RS, Hulstijn W. Psychomotor planning is deficient in recent-onset schizophrenia. Schizophr Res. 2009 Feb;107(2-3):294-302
370. Aukes MF, Alizadeh BZ, Sitskoorn MM, Kemner C, Ophoff RA, Kahn RS. Genetic Overlap Among Intelligence and Other Candidate Endophenotypes for Schizophrenia. Biol Psychiatry. 2009 Mar 15;65(6):527-34
371. Mandl RC, Schnack HG, Luijckx J, van den Heuvel MP, Cahn W, Kahn RS, Hulshoff Pol HE. Tract-based Analysis of Magnetization Transfer Ratio and Diffusion Tensor Imaging of the Frontal and Frontotemporal Connections in Schizophrenia. Schizophr Bull. 2008 Nov 27. [Epub ahead of print]
372. Cahn W, Rais M, Stigter FP, van Haren NE, Caspers E, Hulshoff Pol HE, Xu Z, Schnack HG, Kahn RS. Psychosis and brain volume changes during the first five years of schizophrenia. Eur Neuropsychopharmacol. 2009 Feb 19(2): 147-51
373. Somers M, Sommer IE, Boks MP, Kahn RS. Hand-preference and population schizotypy: A meta-analysis. Schizophr Res. 2009 Mar;108(1-3):25-32

374. Oranje B, Gispens-de Wied CC, Westenberg HG, Kemner C, Verbaten MN, Kahn RS. Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude.. Int J Neuropsychopharmacol. 2009 Jan 21:1-10
375. Van Buuren M, Gladwin TE, Zandbelt BB, van den Heuvel M, Ramsey NF, Kahn RS, Vink M. Cardiorespiratory effects on default-mode network activity as measured with fMRI.. Hum Brain Mapp. 2009 Sept;30(9):3031-42
376. van der Schot AC, Vonk R, Brans RG, van Haren NE, Koolschijn PC, Nuboer V, Schnack HG, van Baal GC, Boomsma DI, Nolen WA, Hulshoff Pol HE, Kahn RS. Influence of genes and environment on brain volumes in twin pairs concordant and discordant for bipolar disorder.. Arch Gen Psychiatry. 2009 Feb;66(2):142-51
377. Morgan BE, Honk JV, Hermans EJ, Scholten MR, Stein DJ, Kahn RS. Gray's BIS/BAS dimensions in non-comorbid, non-medicated social anxiety disorder. World J Biol Psychiatry. 2009 Feb 4:1-4
378. Peper JS, Brouwer RM, Van Baal GC, Schnack HG, Van Leeuwen M, Boomsma DI, Kahn RS, Hulshoff Pol HE. Does having a twin-brother make for a bigger brain?. Eur J Endocrinol. 2009 May;160(5):739-46
379. Luykx JJ, Wolters FJ, Vulink NC, van der Erf M, Wokke JH, Kahn RS. [Neuropsychiatric disorders. Multidisciplinary diagnosis and treatment]. Ned Tijdschr Geneesk. 2009 Jan 17;153(3):75-9. Dutch
380. van den Heuvel MP, Mandl RC, Kahn RS, Hulshoff Pol HE. Functionally linked resting-state networks reflect the underlying structural connectivity architecture of the human brain.. Hum Brain Mapp. 2009 Oct;30(10):3127-41
381. Derks EM, Verweij KH, Kahn RS, Cahn WC. The calculation of familial loading in schizophrenia.. Schizophr Res. 2009 Jun;111(1-3):198-9
382. Peper JS, Schnack HG, Brouwer RM, Van Baal GC, Pjetri E, Székely E, van Leeuwen M, van den Berg SM, Collins DL, Evans AC, Boomsma DI, Kahn RS, Hulshoff Pol HE. Heritability of regional and global brain structure at the onset of puberty: A magnetic resonance imaging study in 9-year-old twin pairs.. Hum Brain Mapp. 2009 Jul;30(7):2184-96
383. Rujescu D, Ingason A, Cichon S, Pietiläinen OP, Barnes MR, Toulopoulou T, Picchioni M, Vassos E, Ettinger U, Bramon E, Murray R, Ruggeri M, Tosato S, Bonetto C, Steinberg S, Sigurdsson E, Sigmundsson T, Petursson H, Gylfason A, Olason PI, Hardarsson G, Jonsdottir GA, Gustafsson O, Fossdal R, Giegling I, Möller HJ, Hartmann AM, Hoffmann P, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Djurovic S, Melle I, Andreassen OA, Hansen T, Werge T, Kiemenev LA, Franke B, Veltman J, Buizer-Voskamp JE; GROUP Investigators, Sabatti C, Ophoff RA, Rietschel M, Nöthen MM, Stefansson K, Peltonen L, St Clair D, Stefansson H, Collier DA. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet. 2009 Mar 1;18(5):988-96
384. Rietkerk T, Boks MP, Sommer IE, de Jong S, Kahn RS, Ophoff RA. Network analysis of positional candidate genes of schizophrenia highlights myelin-related pathways. Mol Psychiatry.

2009 Apr;14(4):353-5

385. Terwisscha van Scheltinga AF, Bakker SC, Kahn RS. Fibroblast Growth Factors in Schizophrenia. Schizophr Bull. 2009 May 8. (Epub ahead of print)
386. Koolschijn PC, van Haren NE, Lenvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS. Brain volume abnormalities in major depressive disorder: A meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp. 2009 Nov;30(11):3719-35
387. van 't Wout M, van Rijn S, Jellema T, Kahn RS, Aleman A. Deficits in implicit attention to social signals in schizophrenia and high risk groups: behavioural evidence from a new illusion. PLoS ONE. 2009;4(5):e5581
388. Laan W, Smeets H, de Wit NJ, Kahn RS, Grobbee DE, Burger H. Glucocorticosteroids associated with a decreased risk of psychosis. J Clin Psychopharmacol. 2009 Jun;29(3):288-90
389. Magnée MJ, Oranje B, van Engeland H, Kahn RS, Kemner C. Cross-sensory gating in schizophrenia and autism spectrum disorder: EEG evidence for impaired brain connectivity? Neuropsychologia. 2009 Jun;47(7):1728-32
390. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindfors N, Riecher-Rössler A, Kahn RS. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009 Jun;166(6):675-82.
391. Grootens KP, van Veelen NM, Peuskens J, Sabbe BG, Thys E, Buitelaar JK, Verkes RJ, Kahn RS. Ziprasidone Vs Olanzapine in Recent-Onset Schizophrenia and Schizoaffective Disorder: Results of an 8-Week Double-Blind Randomized Controlled Trial. Schizophr Bull. 2009 Jun 19 [Epub ahead of print]
392. van den Heuvel MP, Stam CJ, Kahn RS, Hulshoff Pol HE. Efficiency of functional brain networks and intellectual performance. J Neurosci. 2009 Jun 10;29(23):7619-24
393. van 't Wout M, van Rijn S, Jellema T, Kahn RS, Aleman A. Deficits in implicit attention to social signals in schizophrenia and high risk groups: behavioural evidence from a new illusion. PLoS One. 2009;4(5):e5581.
394. Laan W, Smeets H, de Wit NJ, Kahn RS, Grobbee DE, Burger H. Glucocorticosteroids associated with a decreased risk of psychosis. J Clin Psychopharmacol. 2009 Jun;29(3):288-90
395. Magnée MJ, Oranje B, van Engeland H, Kahn RS, Kemner C. Cross-sensory gating in schizophrenia and autism spectrum disorder: EEG evidence for impaired brain connectivity? Neuropsychologia. 2009 Jun;47(7):1728-32
396. Kemner C, Foxe JJ, Tankink JE, Kahn RS, Lamme VA. Abnormal timing of visual feedback processing in young adults with schizophrenia. Neuropsychologia. 2009 Dec;47(14):3105-10
397. Koolschijn PC, van Haren NE, Bakker SC, Hoogendoorn ML, Pol HE, Kahn RS. Effects of brain-

derived neurotrophic factor Val66Met polymorphism on hippocampal volume change in schizophrenia. Hippocampus. 2009 Aug 27 [Epub ahead of print].

398. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietiläinen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Børglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Böttcher Y, Olesen J, Breuer R, Möller HJ, Giegling I, Rasmussen HB, Timm S, Mattheisen M, Bitter I, Réthelyi JM, Magnusdottir BB, Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R, Thorgeirsson TE, Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E, Kiemeny LA; Genetic Risk and Outcome in Psychosis (GROUP), Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de Frutos R, Bramon E, Vassos E, Fraser G, Ettinger U, Picchioni M, Walker N, Toulopoulou T, Need AC, Ge D, Yoon JL, Shianna KV, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jönsson EG, Terenius L, Agartz I, Petursson H, Nöthen MM, Rietschel M, Matthews PM, Muglia P, Peltonen L, St Clair D, Goldstein DB, Stefansson K, Collier DA. Common variants conferring risk of schizophrenia. Nature. 2009 Aug 6;460(7256):744-7
399. Boks MP, Derks EM, Weisenberger DJ, Strengman E, Janson E, Sommer IE, Kahn RS, Ophoff RA. The relationship of DNA methylation with age, gender and genotype in twins and healthy controls. PLoS One. 2009 Aug 26;4(8):e6767
400. Leeuwen, M van, Peper, J.S., Berg, S.M. van den, Brouwer, R.M., Hulshoff Pol, H.E., Kahn, R.S. & Boomsma, D.I. The genetic and environment structure of brain volumes and IQ. Intelligence, 2009, 37(2), 290-290
401. Padmos RC, Van Baal GC, Vonk R, Wijkhuijs AJ, Kahn RS, Nolen WA, Drexhage HA Genetic and environmental influences on pro-inflammatory monocytes in bipolar disorder: a twin study. Arch Gen Psychiatry. 2009 Sep;66(9):957-65
402. Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, Kahn RS; EUFEST group. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: An open randomized clinical trial (EUFEST). Schizophr Res. 2009 Dec: 115(2-3):97-103
403. Galderisi S, Davidson M, Kahn RS, Mucci A, Boter H, Gheorghe MD, Rybakowski JK, Libiger J, Dollfus S, López-Ibor JJ, Peuskens J, Hranov LG, Fleischhacker WW; EUFEST group. Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study. Schizophr Res. 2009, Dec:1152(2-3):104-14
404. Boter H, Derks EM, Fleischhacker WW, Davidson M, Kahn RS; EUFEST Group. Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry. 2010 Jan;71(1):58-65
405. Peper JS, Brouwer RM, van Leeuwen M, Schnack HG, Boomsma DI, Kahn RS, Hulshoff Pol HE. HPG-axis hormones during puberty: A study on the association with hypothalamic and pituitary volumes. Psychoneuroendocrinology. 2010 Jan;35(1):133-40

406. Réthelyi JM, Bakker SC, Polgár P, Czobor P, Strengman E, Pásztor PI, Kahn RS, Bitter I. Association study of NRG1, DTNBP1, RGS4, G72/G30, and PIP5K2A with schizophrenia and symptom severity in a Hungarian sample. Am J Med Genet B Neuropsychiatr Genet. 2010 Apr;153B(3):792-801
407. Koning JP, Tenback DE, Kahn RS, Van Schelven LJ, Van Harten PN. Instrument measurement of lingual force variability reflects tardive tongue dyskinesia. J Med Eng Technol. 2010;34(1):71-7
408. van Hell HH, Vink M, Ossewaarde L, Jager G, Kahn RS, Ramsey NF. Chronic effects of cannabis use on the human reward system: An fMRI study. Eur Neuropsychopharmacol. 2010 Mar;20(3):153-63
409. Peper JS, Brouwer RM, van Leeuwen M, Schnack HG, Boomsma DI, Kahn RS, Hulshoff Pol HE. HPG-axis hormones during puberty: a study on the association with hypothalamic and pituitary volumes. Psychoneuroendocrinology. 2010 Jan;35(1):133-40
410. van Buuren M, Gladwin TE, Zandbelt BB, Kahn RS, Vink M. Reduced functional coupling in the default-mode network during self-referential processing. Hum Brain Mapp. 2010 Aug;31(8):1117-27
411. Liem-Moolenaar M, Te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, Touw D, van Gerven JM. Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol. 2010 Feb 8. [Epub ahead of print]
412. Diederer KM, Neggers SF, Daalman K, Blom JD, Goekoop R, Kahn RS, Sommer IE. Deactivation of the Parahippocampal Gyrus Preceding Auditory Hallucinations in Schizophrenia. Am J Psychiatry. 2010 Apr;167(4):427-35
413. Ingason A, Giegling I, Cichon S, Hansen T, Rasmussen HB, Nielsen J, Jürgens G, Muglia P, Hartmann AM, Strengman E, Vasilescu C, Mühleisen TW, Djurovic S, Melle I, Lerer B, Möller HJ, Francks C, Pietiläinen OP, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Walshe M, Vassos E, Di Forti M, Murray R, Bonetto C, Tosato S; GROUP Investigators, Cantor RM, Rietschel M, Craddock N, Owen MJ, Peltonen L, Andreassen OA, Nöthen MM, St Clair D, Ophoff RA, O'Donovan MC, Collier DA, Werge T, Rujescu D. A large replication study and meta-analysis in European samples provides further support for association of AH11 markers with schizophrenia. Hum Mol Genet, 2010 Apr 1; 19(7):1379-86. Epub 2010 Jan 12
414. Vorstman JA, van Daalen E, Jalali GR, Schmidt ER, Pasterkamp RJ, de Jonge M, Hennekam EA, Janson E, Staal WG, van der Zwaag B, Burbach JP, Kahn RS, Emanuel BS, van Engeland H, Ophoff RA. A double hit implicates DIAPH3 as an autism risk gene. Mol Psychiatry. 2010 Mar 23 (Epub ahead of print)
415. Brouwer RM, Mandl RC, Peper JS, van Baal GC, Kahn RS, boomsma DI, Hulshoff Pol HE. Heritability of DTI and MTR in nine-year-old children. Neuroimage. 2010 Mar 16 (Epub ahead of print)
416. Brans RG, Kahn RS, Schnack HG, van Baal GC, Posthuma D, van Haren NE, Lepage C, Lerch JP, Collins DL, Evans AC, Boomsma DI, Hulshoff Pol HE. Brain plasticity and intellectual ability are influenced by shared genes. J Neurosci. 2010 Apr;30(16):5519-24

417. Friedman JL, Vrijenhoek T, Markx S, Manssen IM, van der Vliet WA, Faas BH, Knoers NV, Cahn W, Kahn RS, Edelmann L, Davis KL, Silverman JM, Brunner HG, Geurts van Kessel A, Wijmenga C, Ophoff RA, Veltman JA. Mol Psychiatry. 2010 Apr 20 CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy. Mol Psychiatry. 2010 Apr 20 (Epub ahead of print)
418. Derks EM, Fleischhacker WW, Boter H, Peuskens J, Kahn RS, EUFEST Study Group. Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4 or 6 weeks of nonresponse? J Clin Psychopharmacol. 2010 Apr;30(2):176-80
419. Gaebel W, Riesbeck M, von Wilmsdorff M, Burns T, Derks EM, Kahn RS, Rössler W, Fleischhacker WW; EUFEST Study Group. Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol. 2010 May;20(5):31-6 (Epub 2010 Mar 3)
420. de Weijer AD, Mandl RC, Sommer IE, Vink M, Kahn RS, Neggers SF. Human fronto-tectal and fronto-striatal-tectal pathways activate differently during anti-saccades. Front Hum Neurosci. 2010 May 26;4:41
421. Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010 May; 71(5):520-7
422. Sahakian BJ, Malloch G, Kennard C; Mental Health Review Group. A UK strategy for mental health and wellbeing. The Lancet. 2010 May 29;375 (9729):1854-5
423. Luykx JJ, Boks MP, Terwindt AP, Bakker S, Kahn RS, Ophoff RA. The involvement of FSK3beta in bipolar disorder: Integrating evidence from multiple types of genetic studies. Eur Neuropsychopharmacol. 2010 June;20(6):357-68. Epub 2010 Mar 11
424. Koolschijn PC, van Haren NE, Schnack HG, Janssen J, Hulshoff Pol HE, Kahn RS. Cortical thickness and voxel-based morphometry in depressed elderly. Eur Neuropsychopharmacol. 2010 Jun;20(6):398-404. Epub 2010 Mar 12
425. van Soelen IL, Brouwer RM, Peper JS, van Beijsterveldt TC, van Leeuwen M, de Vries LS, Kahn RS, Hulshoff Pol HE, Boomsma DI. Effects of gestational age and birth weight on brain volumes in healthy 9 year-old-children. J Pediatr. 2010 Jun;156(6):896-901
426. van Venrooij JA, Fluitman SB, Lijmer JG, Kavelaars A, Heijnen CJ, Westenberg HG, Kahn RS, Gispen-de Wied CC. Impaired neuroendocrine and immune response to acute stress in medication-naïve patients with a first episode of psychosis. Schizophr Bull. 2010 June 17. (Epub ahead of print).
427. Koolschijn PC, van Haren NE, Cahn W, Schnack HG, Janssen J, Klumpers F, Hulshoff Pol HE, Kahn RS. Hippocampal volume change in schizophrenia. J Clin Psychiatry. 2010 Jun;71(6):737-44. Epub 2010 Jan 12

428. Zandi T, havenaar JM, Smits M, Lumburg-Okken AG, van Es H, Cahn W, Algra A, Kahn RS, van den Brink W. First contact incidence of psychotic disorders among native Dutch and Moroccan immigrants in the Netherlands: Influence of diagnostic bias. Schizophr Res. 2010 Jun;119(1-3):27-33. Epub 2010 Mar 23
429. van Haren NE, Koolschijn PC, Cahn W, Schnack HG, Hulshoff Pol HE, Kahn RS. Cigarette smoking and progressive brain volume loss in schizophrenia. Eur Neuropsychopharmacol. 2010 Jul;20(7):454-8. Epub 2010 Mar 15
430. Boks MP, Derks EM, Dolan CV, Kahn RS, Ophoff RA. "Forward genetics" as a method to maximize power and cost-efficiency in studies of human complex traits. Behav Genet. 2010 Jul;40(4):564-71. Epub 2010 Mar 16
431. van Veelen NM, Grootens KP, Peuskens J, Sabbe BG, Salden ME, Verkes RJ, Kahn RS, Sitskoorn MM. Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia. Schizophr Res. 2010 Jul;120(1-3):191-8. Epub 2010 May 20
442. Breetvelt EJ, Boks MP, Numans ME, Selten JP, Sommer IE, Grobbee DE, Kahn RS, Geerlings MI. Schizophrenia risk factors constitute general risk factors for psychiatric symptoms in the population. Schizophr Res. 2010 Jul;120(1-3):184-90. Epub 2010 Apr 24
443. van Lutterveld R, Oranje B, Kemner C, Abramovic L, Willems AE, Boks MP, Glenthøj BY, Kahn RS, Sommer IE. Increased psychophysiological parameters of attention in non-psychotic individuals with auditory verbal hallucinations. Schizophr Res 2010 Aug;121(1-3):153-159. Epub 2010 May 21
444. Boonstra G, Grobbee DE, Hak E, Kahn RS, Burger H. Initiation of antipsychotic treatment by general practitioners. A case-control study. J Eval Clin Pract. 2010 Aug 26.
445. van Veelen NM, Vink M, Ramsey NF, Kahn RS. Left dorsolateral prefrontal cortex dysfunction in medication-naïve schizophrenia. Schizophr Res. 2010 Oct;123(1):22-9.
446. Magnée MJ, Kahn RS, Cahn W, Kemner C. More prolonged brain activity related to gaze cueing in schizophrenia. Clin Neurophysiol. 2010 Aug 9.
447. van Buuren M, Gladwin TE, Zandbelt BB, Kahn RS, Vink M. Reduced functional coupling in the default-mode network during self-referential processing. Hum Brain Mapp. 2010 Aug;31(8):1117-27
448. Rais M, van Haren NE, Cahn W, Schnack HG, Lepage C, Collins L, Evans AC, Hulshoff Pol HE, Kahn RS. Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia. Eur Neuropsychopharmacol. 2010 Sep 20.
449. van der Schot AC, Vonk R, Brouwer RM, van Baal GC, Brans RG, van Haren NE, Schnack HG, Boomsma DI, Nolen WA, Pol HE, Kahn RS. Genetic and environmental influences on focal brain density in bipolar disorder. Brain. 2010 Sep 12
450. Grootens KP, van Veelen NM, Sitskoorn MM, Sabbe BG, Peuskens J, Buitelaar JK, Verkes RJ, Kahn RS. Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset

- schizophrenia. Eur Neuropsychopharmacol. 2010 Sep 10
451. Vinkers CH, Mirza NR, Olivier B, Kahn RS. The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline. Expert Opin Investig Drugs. 2010 Oct;19(10):1217-33.
 452. Brouwer RM, Mandl RC, Peper JS, van Baal GC, Kahn RS, Boomsma DI, Hulshoff Pol HE. Heritability of DTI and MTR in nine-year-old children. Neuroimage. 2010 Nov 15;53(3):1085-92
 453. Rais M, van Haren NE, Cahn W, Schnack HG, Lepage C, Collins L, Evans AC, Hulshoff Pol HE, Kahn RS. Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia. Eur Neuropsychopharmacol. 2010 Sep 20.
 454. Winkel R van, Genetic Risk and Outcome of Psychosis (GROUP) Investigators. Family-Based Analysis of Genetic Variation Underlying Psychosis-Inducing Effects of Cannabis. Sibling Analysis and Proband Follow-up. Arch Gen Psych, 2010. 152, nov 1, E1-E10
 455. Muntjewerff JW, Ophoff RA, Buizer-Voskamp JE, Strengman E, den Heijer M, Group Consortium. Effects of season of birth and a common MTHFR gene variant on the risk of schizophrenia, European Neuropharmacology, 2010: 1-6
 456. Boonstra G, Burger H, Grobbee DE, Kahn RS. Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenic patients. Results from an aborted randomised trial. International Journal of Psychiatry in Clinical practice, 2010 early online, 1-7
 457. Genetic Risk and Outcome in Psychosis (GROUP) Investigators. Evidence That Familial Liability for Psychosis Is Expressed as Differential Sensitivity to Cannabis: An Analysis of Patient-Sibling and Sibling-Control Pairs. Arch Gen Psychiatry. 2010 Oct 4.
 458. Schubart CD, van Gastel WA, Breetvelt EJ, Beetz SL, Ophoff RA, Sommer IE, Kahn RS, Boks MP. Cannabis use at a young age is associated with psychotic experiences. Psychol Med. 2010 Oct 7:1-10.
 459. Ziermans TB, Schothorst PF, Schnack HG, Koolschijn PC, Kahn RS, van Engeland H, Durston S. Progressive Structural Brain Changes During Development of Psychosis. Schizophr Bull. 2010 Oct 7
 460. van Winkel R; Genetic Risk and Outcome of Psychosis (GROUP) Investigators. Family-Based Analysis of Genetic Variation Underlying Psychosis-Inducing Effects of Cannabis: Sibling Analysis and Proband Follow-up. Arch Gen Psychiatry. 2010 Nov 1.
 461. Schnack HG, van Haren NE, Brouwer RM, van Baal GC, Picchioni M, Weisbrod M, Sauer H, Cannon TD, Huttunen M, Lepage C, Collins DL, Evans A, Murray RM, Kahn RS, Hulshoff Pol HE. Mapping reliability in multicenter MRI: Voxel-based morphometry and cortical thickness. Hum Brain Mapp. 2010 Dec;31(12):1967-82
 462. Diederik KM, De Weijer AD, Daalman K, Blom JD, Neggers SF, Kahn RS, Sommer IE. Decreased language lateralization is characteristic of psychosis, not auditory hallucinations. Brain. 2010 Dec;133(Pt 12):3734-44.

463. van den Heuvel MP, Mandl RC, Stam CJ, Kahn RS, Hulshoff Pol HE. Aberrant frontal and temporal complex network structure in schizophrenia: a graph theoretical analysis. *J Neurosci*. 2010 Nov 24;30(47):15915-26.
464. Slotema CW, Blom JD, de Weijer AD, Diederens KM, Goekoop R, Looijestijn J, Daalman K, Rijkaart AM, Kahn RS, Hoek HW, Sommer IE. Can Low-Frequency Repetitive Transcranial Magnetic Stimulation Really Relieve Medication-Resistant Auditory Verbal Hallucinations? Negative Results from a Large Randomized Controlled Trial. *Biol Psychiatry*. 2010 Dec 6.
465. Zandi T, Havenaar JM, Kahn RS, van den Brink W. Incidence of schizophrenia among Moroccan immigrants to the Netherlands. Response to letter written by Selten et al. to *Schizophrenia Research*. *Schizophr Res*. 2010 Dec 10.
466. Schubart CD, Boks MP, Breetvelt EJ, van Gastel WA, Groenwold RH, Ophoff RA, Sommer IE, Kahn RS. Association between cannabis and psychiatric hospitalization. *Acta Psychiatr Scand*. 2010 Dec 28.
467. van Veelen NM, Vink M, Ramsey NF, Sommer IE, van Buuren M, Hoogendam JM, Kahn RS. Reduced language lateralization in first-episode medication-naive schizophrenia. *Schizophr Res*. 2011 Jan 13
468. Boos HB, Cahn W, van Haren NE, Derks EM, Brouwer RM, Schnack HG, Hulshoff Pol HE, Kahn RS. Focal And Global Brain Measurements in Siblings of Patients With Schizophrenia. *Schizophr Bull*. 2011 Jan 17. [Epub ahead of print]PMID: 21242319

BOOKS AND CHAPTERS

01. van Praag, H.M.; Kahn, R.S.; Asnis, G.M.; Wetzler, S.; Brown, S.; Bleich, A.; Korn, M. Beyond nosology in biological psychiatry. 5HT disturbances in mood, aggression and anxiety disorders. In: (Macmillan) New directions in depression research, 1987
02. van Praag, H.M.; Verhoeven, W.M.A.; Kahn, R.S. Psychofarmaca. Van Gorcum & Comp, BV, Assen, The Netherlands, 1988
03. van Praag, H.M.; Asnis, G.M., Kahn, R.S.; Brown, S.L.; Korn, M.; Friedman J.M.; Wetzler, S. Beyond serotonin: a multi-aminergic perspective of abnormal behavior. In: The role of serotonin in psychiatric disorders (Brown & van Praag, eds), Brunner/Mazel, New York, NY, 1991
04. Kahn, R.S.; Kalus, O.; Wetzler, S; van Praag, H.M. The role of serotonin in the regulation of anxiety. In: The role of serotonin in psychiatric disorders (Brown & van Praag, eds), Brunner/Mazel, New York, NY, 1991
05. Kahn, R.S.; van Praag, H.M. Angststoornissen. In: Het Psychiatrisch Formularium (Pepplinkhuizen, Verhoeven, van der Does, Sitsen eds). Erasmus Publishing, Rotterdam, 1991

06. Kahn, R.S.; van Praag, H.M. Stemningsstoornissen. In: Het Psychiatrisch Formularium (Pepplinkhuizen, Verhoeven, van der Does, Sitsen eds). Erasmus Publishing, Rotterdam, 1991
07. Iqbal, N.; Asnis, G.M.; Wetzler, S.; Kahn, R.S.; Kay, S.; van Praag, H.M. The MCPP challenge test in schizophrenia: hormonal and behavioral responses. In: Biological Psychiatry, Vol I. (Racagni et al, eds). Elsevier Science Publishers, B.V., The Netherlands, 1992
08. Wetzler, S.; Kahn, R.S.; Asnis, G.M.; Korn, M.; van Praag, H.M. Serotonin receptor sensitivity and aggression. In: Biological Psychiatry, Vol I. (Racagni et al, eds). Elsevier Science Publishers B.V., The Netherlands, 1992
09. Kahn, R.S.; Moore, C. Serotonin in the pathogenesis of anxiety. In: Biology of Anxiety Disorders (Hoehn-Saric, ed), American Psychiatric Press, Washinton, DC, 1993
10. Stern R.G.; Kahn, R.S.; Davidson, M. Predictors of response to neuroleptic treatment in schizophrenia. In: Psychiatric Clinics of North America (Powchik & Schulz, eds), Saunders, Philadelphia, PA, 1993
11. Kahn, R.S.; Westenberg, H.G.M.; Moore, C. Increased serotonin function and panic disorder. In: Panic Disorder (Asnis & van Praag, eds). Wiley & Sons, New York, NY, 1995
12. Kahn, R.S.; Davis K.L. New developments in dopamine and schizophrenia. In: Psychopharmacology: The fourth generation of progress (Bloom & Kupfer, eds), Raven Press, New York, NY, 1995
13. Kahn, R.S.; Davidson, M. Dopamine in schizophrenia. In: Advances in the neurobiology of schizophrenia (Den Boer, Westenberg & van Praag, eds), Wiley & Sons, New York, NY, 1995
14. Van den Bosch, R.J. en Kahn, R.S. Classificatie en diagnostiek van schizofrenie. In: Schizofrenie: Onderzoek en implicaties voor behandeling (Dingemans, Van den Bosch, Kahn & Schene eds). Bohn Stafleu Van Loghum, Houten/Diegem, The Netherlands, 1995
15. Kahn, R.S. Het werkingsmechanisme van klassieke antipsychotica. In: Schizofrenie: Onderzoek en implicaties voor behandeling (Dingemans, Van den Bosch, Kahn & Schene eds). Bohn Stafleu Van Loghum, Houten/Diegem, The Netherlands, 1995
16. Kahn, R.S.; Stern, R.G; Davidson, M. Voorspelling van de resultaten van antipsychotica bij schizofrene patiënten. In: Schizofrenie: Onderzoek en implicaties voor de behandeling (Dingemans, Van den Bosch, Kahn & Schene eds). Bohn Stafleu Van Loghum, Houten/Diegem, The Netherlands, 1995
17. Van Berckel, B.N.M.; Van Ree, J.M.; Kahn, R.S. Atypische neuroleptica. In: Schizofrenie: Onderzoek en implicaties voor de behandeling (Dingemans, Van den Bosch, Kahn & Schene eds). Bohn Stafleu Van Loghum, Houten/Diegem, The Netherlands, 1995
18. Hulshoff Pol, H.E.; Baaré, W.F.C.; Kahn, R.S. Beeldvormend functie-onderzoek bij patienten met schizofrenie. In: Schizofrenie: Onderzoek en implicaties voor de behandeling (Dingemans, Van den Bosch, Kahn & Schene eds). Bohn Stafleu Van Loghum, Houten/Diegem, The Netherlands, 1995

19. Kahn, R.S.; Davidson, M.; Davis, K.L. Dopamine and schizophrenia revisited. In: Biology of schizophrenia and affective disease (Watson SJ, ed). American Psychiatric Press, Inc., Washington, DC, 1996
20. Kahn, R.S.; van Praag, H.M. De rol van serotonine bij schizofrenie. In: Leerboek Schizofrenie (Den Boer, Van den Bosch, eds). De Tijdstroom, Utrecht, The Netherlands, 1996
21. Kahn, R.S.; van Praag, H.M. Dopamine, serotonin, and their interactions in schizophrenia. In: Serotonin in antipsychotic treatment (Kane, JM ed), Marcel Dekker, New York, NY, 1996
22. Stern, R.G.; Kahn, R.S.; Davidson, M. Review of plasma HVA studies in schizophrenia. In: Plasma homovanillic acid studies in schizophrenia (Friedhoff AJ, Amin F, ed), American Psychiatric Press, Chicago, IL, 1997
23. Kahn, R.S. Gids Pillen en Psychiatrie (Kahn ed) Balans, Amsterdam, 1997, 1998, 2008.
24. Kahn, R.S.; Zitman, F.G. Farmacotherapie in de psychiatrie. Elsevier/Bunge, Maarssen, Elsevier/Bunge, Maarssen, 1999
25. Kahn, R.S. Schizofrenie en aan schizofrenie verwante stoornissen. In: Farmacotherapie in de psychiatrie (Kahn & Zitman, eds). Elsevier/Bunge, Maarssen, 1999
26. Kahn, R.S.; Hulshoff Pol, H.H. Beeldvormend onderzoek in de psychiatrie. In: Jaarboek Psychiatrie en Psychotherapie 6 (Heeren, Van der Mast, Schnabel, Trijsburg, Vandereycken, Verhulst, Van der Velden, eds). Bohn Stafleu Van Loghum, Houten, 1999
27. Kahn, R.S.; Van Ree, J.M. The pharmacotherapy of schizophrenia in clinical practice. In: Schizophrenia (Maj & Sartorius, eds.) WPA Series Evidence and Experience in Psychiatry, John Wiley & Sons, Ltd, New York, 1999
28. Sitskoorn, M.M.; Appels, M.C.M.; Hulshoff Pol, H.H.; Kahn, R.S. Evidence of fronto-thalamic involvement in schizophrenia. In: Progress in brain Research (Uylings, Van Eden, De Bruin, Feenstra & Pennartz, eds) Elsevier Science BV, 2000
29. J.P.Selten, N.D.Veen, W.G.Feller, J.D.Blom, H.W.Hoek en R.S.Kahn. Incidentie van schizofrenie bij migranten in Nederland. In: Jaarboek voor psychiatrie en psychotherapie 2003-2004 8 (Schene, Heeren, Henselmans, Sabbe, van Weeghel) Bohn Stafleu Van Loghum, Houten/Mechelen 2003
30. Aleman A, Kahn RS. De Haan EHF. Schizofrenie: hallucinaties. In: Cognitieve neuropsychiatrie (Eling, De Haan, Hijman & Schmand eds). Boom, Amsterdam, 2003.
31. Aleman A, Kahn RS. Hostility and aggression in schizophrenia: efficacy of atypical antipsychotics. In: Schizophrene störungen: state of the art III (Fleishhacker & Hummer eds). Verlag Integrative Psychiatrie, Innsbruck 2004

- 32 Cahn W, Bruggeman R, Kahn R. Schizofrenie. In: Handboek Neurobiologische psychiatrie (Hovens, Loonen & Timmerman (eds). de Tijdstroom Uitgeverij, Utrecht 2004, ISBN 90 5898 049 9, NUR 875
- 33 De Haan L, Kahn R. Psychotische stoornissen. In: Leerboek Psychiatrie (Hengeveld, van Balkom eds). De Tijdstroom uitgeverij, 2005, ISBN 90 5898 076 6 / 5898 094 4, NUR 875
- 34 Kahn René. Onze Hersenen., Over de smalle grens tussen normaal en abnormaal. Uitgeverij Balans, Amsterdam 2006, 2007, 2008 ISBN 90 50187129, NUR 875 (9 printings)
- 35 Kahn René. In de spreekkamer van de psychiater. Uitgeverij Balans, Amsteram 2008, ISBN 978 90 5018 8814, NUR 875 (6 printings)